<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">43333</article-id><article-id pub-id-type="doi">10.7554/eLife.43333</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-85621"><name><surname>Lieb</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-125448"><name><surname>Blaha-Ostermann</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-125449"><name><surname>Kamper</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-133134"><name><surname>Rippka</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-133135"><name><surname>Schwarz</surname><given-names>Cornelia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-125450"><name><surname>Ehrenhöfer-Wölfer</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-85626"><name><surname>Schlattl</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-57505"><name><surname>Wernitznig</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-125451"><name><surname>Lipp</surname><given-names>Jesse J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-125452"><name><surname>Nagasaka</surname><given-names>Kota</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0765-638X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-85620"><name><surname>van der Lelij</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-125453"><name><surname>Bader</surname><given-names>Gerd</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8410-3415</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-133136"><name><surname>Koi</surname><given-names>Minoru</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-112045"><name><surname>Goel</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-125454"><name><surname>Neumüller</surname><given-names>Ralph A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-85633"><name><surname>Peters</surname><given-names>Jan-Michael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2820-3195</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-57504"><name><surname>Kraut</surname><given-names>Norbert</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-85632"><name><surname>Pearson</surname><given-names>Mark A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" corresp="yes" id="author-84015"><name><surname>Petronczki</surname><given-names>Mark</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0139-5692</contrib-id><email>mark_paul.petronczki@boehringer-ingelheim.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" corresp="yes" id="author-124970"><name><surname>Wöhrle</surname><given-names>Simon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2478-7333</contrib-id><email>simon.woehrle@boehringer-ingelheim.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf16"/></contrib><aff id="aff1"><label>1</label><institution>Boehringer Ingelheim RCV GmbH &amp; Co KG</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution>Research Institute of Molecular Pathology</institution><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Division of Gastroenterology, Department of Internal Medicine, Comprehensive Cancer Center</institution><institution>University of Michigan</institution><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Center for Gastrointestinal Research, Baylor Scott &amp; White Research Institute and Charles A. Sammons Cancer Center</institution><institution>Baylor University Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, Davis</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Settleman</surname><given-names>Jeffrey</given-names></name><role>Senior Editor</role><aff><institution>Calico Life Sciences</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>03</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e43333</elocation-id><history><date date-type="received" iso-8601-date="2018-11-02"><day>02</day><month>11</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2019-03-14"><day>14</day><month>03</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Lieb et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Lieb et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-43333-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.43333.001</object-id><p>Targeted cancer therapy is based on exploiting selective dependencies of tumor cells. By leveraging recent functional screening data of cancer cell lines we identify Werner syndrome helicase (WRN) as a novel specific vulnerability of microsatellite instability-high (MSI-H) cancer cells. MSI, caused by defective mismatch repair (MMR), occurs frequently in colorectal, endometrial and gastric cancers. We demonstrate that WRN inactivation selectively impairs the viability of MSI-H but not microsatellite stable (MSS) colorectal and endometrial cancer cell lines. In MSI-H cells, WRN loss results in severe genome integrity defects. ATP-binding deficient variants of WRN fail to rescue the viability phenotype of WRN-depleted MSI-H cancer cells. Reconstitution and depletion studies indicate that WRN dependence is not attributable to acute loss of MMR gene function but might arise during sustained MMR-deficiency. Our study suggests that pharmacological inhibition of WRN helicase function represents an opportunity to develop a novel targeted therapy for MSI-H cancers.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>WRN</kwd><kwd>helicase</kwd><kwd>mismatch repair</kwd><kwd>microsatellite instability</kwd><kwd>colorectal cancer</kwd><kwd>targeted therapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004410</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nagasaka</surname><given-names>Kota</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000854</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nagasaka</surname><given-names>Kota</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004955</institution-id><institution>Austrian Research Promotion Agency</institution></institution-wrap></funding-source><award-id>FFG 834223</award-id><principal-award-recipient><name><surname>Peters</surname><given-names>Jan-Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004955</institution-id><institution>Austrian Research Promotion Agency</institution></institution-wrap></funding-source><award-id>FFG 852936</award-id><principal-award-recipient><name><surname>Peters</surname><given-names>Jan-Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>693949</award-id><principal-award-recipient><name><surname>Peters</surname><given-names>Jan-Michael</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Targeting Werner syndrome helicase might constitute a novel opportunity for the treatment of a clinically defined subset of patients harboring MSI-H/MMR-deficient tumors.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Defects in components of the DNA repair machinery, such as <italic>BRCA1/2</italic> mutations or impaired DNA mismatch repair (MMR), are a common characteristic of tumor cells, accelerating the accumulation of DNA mutations or chromosomal aberrations that are required for neoplastic growth and transformation (<xref ref-type="bibr" rid="bib28">Kinzler and Vogelstein, 1997</xref>). Plasticity of genome stability pathways permits tumor cells to tolerate the loss of individual DNA repair genes and leads to synthetic lethality (SL) upon targeting the compensating repair mechanism (<xref ref-type="bibr" rid="bib46">Nickoloff et al., 2017</xref>). The first clinically approved drugs exploiting such a SL interaction are Poly(ADP-Ribose) Polymerase (PARP) inhibitors for therapy of BRCA1/BRCA2-deficient tumors (<xref ref-type="bibr" rid="bib27">Kaufman et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Lord and Ashworth, 2017</xref>).</p><p>MMR deficiency is caused by inactivation of genes of the DNA repair machinery involved in the resolution of nucleotide base-base mismatches during DNA replication (<xref ref-type="bibr" rid="bib24">Jiricny, 2006</xref>; <xref ref-type="bibr" rid="bib33">Kunkel and Erie, 2015</xref>). MMR defects lead to characteristic variations in the length of tandem nucleotide repeats across the genome, known as microsatellite instability (MSI) (<xref ref-type="bibr" rid="bib13">Ellegren, 2004</xref>). Germline mutations in MMR genes, most commonly MLH1, MSH2, MSH6 and PMS2, are causative for Lynch syndrome, a cancer predisposition condition associated with increased lifetime risk to develop colorectal cancer (CRC) or other tumor types including endometrial and gastric carcinoma (<xref ref-type="bibr" rid="bib18">Hampel et al., 2005</xref>; <xref ref-type="bibr" rid="bib41">Lynch and Krush, 1971</xref>; <xref ref-type="bibr" rid="bib40">Lynch et al., 2015</xref>). In sporadic, nonhereditary CRC, MSI is frequently observed due to epigenetic silencing of MLH1 (<xref ref-type="bibr" rid="bib12">Cunningham et al., 1998</xref>; <xref ref-type="bibr" rid="bib20">Herman et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Kane et al., 1997</xref>; <xref ref-type="bibr" rid="bib32">Kuismanen et al., 2000</xref>). MSI-high (MSI-H) tumors display a hypermutator phenotype (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>), which entails increased immunogenicity, amendable to therapy with immune checkpoint inhibitors (<xref ref-type="bibr" rid="bib35">Le et al., 2015</xref>). However, targeted therapies directly exploiting the MMR-deficient status of tumor cells do not exist.</p><p>Werner syndrome helicase (WRN) is a member of the RecQ DNA helicase subfamily (<xref ref-type="bibr" rid="bib11">Croteau et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Yu et al., 1996</xref>). RecQ helicases are involved in multiple DNA processing steps including DNA replication, double-strand break repair, transcription and telomere maintenance and are therefore considered to serve as ‘genome caretakers’ (<xref ref-type="bibr" rid="bib9">Chu and Hickson, 2009</xref>; <xref ref-type="bibr" rid="bib11">Croteau et al., 2014</xref>). The critical function of this protein family in genome maintenance is underscored by the fact that defects in three of the five family members – WRN, Bloom Syndrome RecQ Like Helicase (BLM) and RecQ Like Helicase 4 (RECQL4) – give rise to human disease syndromes associated with developmental defects and cancer predisposition (<xref ref-type="bibr" rid="bib6">Brosh, 2013</xref>; <xref ref-type="bibr" rid="bib49">Oshima et al., 2017</xref>). Specifically, patients with Werner syndrome display a premature ageing phenotype including arteriosclerosis, type II diabetes and osteoporosis and are prone to develop tumors of mesenchymal origin, such as soft tissue sarcoma or osteosarcoma (<xref ref-type="bibr" rid="bib16">Goto et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">Hickson, 2003</xref>; <xref ref-type="bibr" rid="bib34">Lauper et al., 2013</xref>). WRN is unique among RecQ family helicases in possessing 3’−5’ exonuclease activity (<xref ref-type="bibr" rid="bib22">Huang et al., 1998</xref>; <xref ref-type="bibr" rid="bib25">Kamath-Loeb et al., 1998</xref>; <xref ref-type="bibr" rid="bib54">Shen et al., 1998</xref>).</p><p>In contrast to the previously described tumor-suppressive role of WRN, we demonstrate in this study that WRN possesses a context-dependent critical pro-survival function for cancer cells. By leveraging a recently defined map of cancer cell specific vulnerabilities (<xref ref-type="bibr" rid="bib44">McDonald et al., 2017</xref>) and a comprehensive molecular characterization of cancer cell models (<xref ref-type="bibr" rid="bib3">Barretina et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Streit et al., 2019</xref>) we identify WRN helicase as a selective dependency in MSI-H cancer cell lines.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>WRN dependency is associated with MSI-H status of cancer cells</title><p>WRN was identified as a potential selective dependency in a subset of 398 cancer cell models in a recent pooled shRNA viability screen covering approximately 8000 genes (Project DRIVE) (<ext-link ext-link-type="uri" xlink:href="https://oncologynibr.shinyapps.io/drive/">https://oncologynibr.shinyapps.io/drive/</ext-link>; <xref ref-type="bibr" rid="bib44">McDonald et al., 2017</xref>). A genomic or expression-based biomarker predictive for WRN dependency was unknown. Depletion of WRN exclusively affects viability of a subset of CRC, gastric and endometrial cancer cell models reflected by RSA (<underline>r</underline>edundant <underline>s</underline>iRNA <underline>a</underline>ctivity) sensitivity scores ≤−3, indicative of cell essentiality (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Intriguingly, CRC, gastric and endometrial cancers are the three human malignancies with the highest frequency of MSI-H status (<xref ref-type="bibr" rid="bib10">Cortes-Ciriano et al., 2017</xref>). This raised the possibility that WRN represents a selective dependency in MSI-H cell lines.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.002</object-id><label>Figure 1.</label><caption><title>WRN is a selective dependency in MSI-H cancer cell models.</title><p>(<bold>A</bold>) WRN shRNA activity by RSA score in pooled shRNA depletion screens from Project DRIVE (<xref ref-type="bibr" rid="bib44">McDonald et al., 2017</xref>). Cell lines were binned according to tumor type. (<bold>B</bold>) MSS/MSI-H status and WRN RSA of CRC, endometrial and gastric cancer models from Project DRIVE.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>WRN dependency correlates with MMR gene mutation status and MLH1 expression.</title><p>(<bold>A</bold>) Receiver operating characteristic curve and variable importance plot for Random Forest model. Note: &lt;gene &gt;_st denotes the mutational status of respective gene whereas &lt;gene &gt; denotes the expression of the respective gene in the variable importance plot. (<bold>B</bold>) MLH1 mRNA TPM and WRN RSA of cancer models from Project DRIVE. Genes involved in MMR are indicated in red font. Data information: Cell line mutation and expression data were derived from the Ordino database (<xref ref-type="bibr" rid="bib56">Streit et al., 2019</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig1-figsupp1-v1.tif"/></fig></fig-group><p>In order to explore this hypothesis we developed a Random Forest model using an MSI feature list defined by Boland and Goel (<xref ref-type="bibr" rid="bib5">Boland and Goel, 2010</xref>). This model classifies WRN sensitive and insensitive cell lines with an accuracy of 0.89 and a recall rate for sensitive lines of 0.69. Importantly, no true insensitive cell lines are classified as sensitive (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). An analysis of variable importance revealed MLH1 expression as the feature most highly associated with the classification outcome, in line with the frequent inactivation of the MLH1 gene in MSI-H CRC (<xref ref-type="bibr" rid="bib12">Cunningham et al., 1998</xref>; <xref ref-type="bibr" rid="bib20">Herman et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Kane et al., 1997</xref>; <xref ref-type="bibr" rid="bib32">Kuismanen et al., 2000</xref>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Consistently, WRN dependency anti-correlates with MLH1 mRNA expression levels among the cell models used in Project DRIVE (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>; p=1.02*10<sup>−4</sup>, Fisher’s exact test, stratification of MLH1-low and -high expressing cell models according to median MLH1 expression [TPM 37.44]).</p><p>Next, we wanted to experimentally validate the MSI status in a select set of cell lines. To this end, we used a fluorescent PCR-based analysis of five mononucleotide microsatellite markers to determine the MSS/MSI-H status of a subset of CRC, gastric and endometrial cancer cell models (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In addition, we utilized a comprehensive MSS/MSI-H status annotation of CRC cell models reported by Medico and colleagues (<xref ref-type="bibr" rid="bib45">Medico et al., 2015</xref>). Analysis of gene dependency and MSS/MSI-H status data revealed that WRN dependency was strongly associated with MSI-H status across CRC, gastric and endometrial models (p=4.91*10<sup>−8</sup>, Fisher’s exact test). Of the 18 cell lines classified as MSI-H, 15 cell lines (83%) were sensitive to WRN depletion using an RSA value of ≤−3 to define WRN dependency (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In contrast, WRN is dispensable for viability in all MSS cell models (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Our analysis suggests that MSI-H status is a strong predictor for WRN sensitivity of cancer cells.</p></sec><sec id="s2-2"><title>WRN depletion by siRNA selectively impairs viability of MSI-H CRC and endometrial cancer cell lines</title><p>To experimentally corroborate the WRN dependency of MSI-H cancer cells, we applied short-interfering RNA (siRNA)-mediated knock-down of WRN in a panel of three MSS (SK-CO-1, CaCo-2, SW480) and three MSI-H (HCT 116, RKO, SNU-C4) CRC cell lines. In agreement with the results from Project DRIVE, WRN depletion using a mixture of four siRNA duplexes (Pool) or an individual siRNA (#1) targeting WRN profoundly affected viability in MSI-H, but not in MSS CRC models (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In contrast, depletion of the known essential mitotic kinase PLK1, had a detrimental effect on viability of both MSS and MSI-H cell lines. Efficient depletion of WRN protein following siRNA transfection was confirmed by immunoblotting (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The selective dependency on WRN was mirrored in colony formation assays with two MSS (LS1034, SK-CO-1) and two MSI-H cell lines (HCT 116, RKO) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Likewise, we observed that WRN knock-down impaired viability of three MSI-H endometrial carcinoma cells lines (HEC-265, ISHIKAWA, HEC-6), but not the MSS cell line MFE-280 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). WRN mRNA levels were similarly reduced upon transfection of pooled or individual WRN-targeting siRNAs in all four endometrial carcinoma models (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.004</object-id><label>Figure 2.</label><caption><title>Loss of WRN selectively impairs viability of MSI-H CRC and endometrial cancer cell models.</title><p>(<bold>A</bold>) MSS and MSI-H CRC cell lines were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to non-targeting control (NTC) siRNA. WRN siRNA knock-down efficacy was analyzed by immunoblotting. Protein lysates were prepared 72 hr after transfection. GAPDH expression was used to monitor equal loading. (<bold>B</bold>) Crystal violet staining of MSS and MSI-H CRC lines treated as in panel A. (<bold>C</bold>) Cell viability analysis of MSS and MSI-H endometrial cell lines treated as in panel A. Data information: In (<bold>A</bold> and <bold>C</bold>), data are presented as mean ± SD of three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.005</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Non-transformed cells do not display WRN dependency.</title><p>(<bold>A</bold>) WRN siRNA knock-down efficacy in endometrial carcinoma cell models was analyzed by qRT-PCR. RNA lysates were prepared 72 hr after transfection. WRN mRNA expression is normalized to 18S rRNA levels (n = 1 experimental replicate). (<bold>B</bold>) Non-transformed hTERT RPE-1 and HCT 116 cells were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to NTC siRNA. WRN siRNA knock-down efficacy was analyzed by immunoblotting. Protein lysates were prepared 72 hr after transfection. GAPDH expression was used to monitor equal loading. (<bold>C</bold>) <italic>TP53</italic>-wild-type CRC cell lines SK-CO-1 and HCT 116 cells were transfected with the indicated siRNAs. Cell viability and WRN siRNA knock-down efficacy was analyzed as in panel B. Data information: In (<bold>B</bold> and <bold>C</bold>) data are presented as mean ± SD of two independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.006</object-id><label>Figure 2—figure supplement 2.</label><caption><title>MLH1/MSH3 reconstitution in HCT 116 CRC cells does not alleviate WRN dependency.</title><p>(<bold>A</bold>) HCT 116 cell lines were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to non-targeting control (NTC) siRNA. (<bold>B</bold>) WRN siRNA knock-down efficacy was analyzed by qRT-PCR. RNA lysates were prepared 48 hr after transfection. WRN mRNA expression is normalized to 18S rRNA levels. (<bold>C</bold>) Reconstitution of MLH1 and MSH3 was determined by immunoblot, Actin expression was used to monitor equal loading. Data information: In (<bold>A</bold>), data are presented as mean ± SD of three to six independent experiments. In (<bold>B</bold>), data are presented as mean ± SD of two independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.007</object-id><label>Figure 2—figure supplement 3.</label><caption><title>WRN inactivation does not elicit dependency on MLH1 or MSH3 in MSS SW480 CRC cells.</title><p>(<bold>A</bold>) SW480 monoclonal cell lines were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to non-targeting control (NTC) siRNA. Knock-out of WRN was confirmed by immunoblot, Actin expression was used to monitor equal loading. (<bold>B</bold>) MLH1 and MSH3 siRNA knock-down efficacy was analyzed by qRT-PCR. RNA lysates were prepared 48 hr after transfection. MLH1 and MSH3 mRNA expression is normalized to 18S rRNA levels. Data information: In (<bold>A</bold>), data are presented as mean ± SD of three independent experiments. In (<bold>B</bold>), data are presented as mean ± SD of two independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig2-figsupp3-v1.tif"/></fig></fig-group><p>Similar to MSS cancer models, non-transformed telomerase-immortalized human retinal pigment epithelial cells (hTERT RPE-1) did not display sensitivity to knock-down of WRN (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). It is noteworthy, that the depletion of the related RecQ helicase BLM significantly impaired viability of hTERT RPE-1, but not HCT 116 cells. These RNAi experiments demonstrate that depletion of WRN abrogates viability in MSI-H but not MSS or non-transformed cells. To assess a potential mechanism to bypass WRN dependence in MSI-H cancer cells, we tested whether co-depletion of p53 and WRN in the <italic>TP53</italic>-wild-type MSI-H CRC line HCT 116 would reverse the sensitivity to WRN knock-down. However, WRN/p53 co-depletion exacerbated the reduction in viability compared to WRN knock-down alone (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). <italic>TP53</italic>-wild-type MSS CRC SK-CO-1 cells were affected neither by individual or dual knock-down of WRN and p53. Interestingly, in both cell lines we observed a slight elevation of p53 protein levels upon WRN depletion (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><p>To determine whether reconstitution of MLH1 and MSH3 in the MSI-H CRC line HCT 116 would revert WRN dependence, we utilized variants of HCT 116 harboring copies of human chromosome 2 (+ch2, control line), chromosome 3 (+ch3, MLH1 reconstitution) or chromosome 3 and 5 (+ch3+ch5, MLH1 and MSH3 reconstitution) derived from normal fibroblasts (<xref ref-type="bibr" rid="bib19">Haugen et al., 2008</xref>; <xref ref-type="bibr" rid="bib30">Koi et al., 1994</xref>). In both HCT 116 +ch3 and HCT 116 +ch3+ch5 cell lines, we noticed only a modest increase of viability upon WRN knock-down compared to the parental cells or the HCT 116 +ch2 control line (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>) despite equally potent WRN knock-down in all models (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). Reconstitution of MLH1 and MSH3 expression in HCT 116 +ch3 and HCT 116 +ch3+ch5 was confirmed by immunoblotting (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). In a reciprocal approach, we monitored whether individual or combined knock-down of MLH1 and MSH3 would elicit differential effects on the viability of WRN-proficient versus WRN-knock-out cell models. To this end, using CRISPR-Cas9 we generated two WRN knock-out SW480 monoclonal lines (WRN KO #1 and #2) and a non-edited, WRN-proficient SW480 monoclonal control line (parental). Loss of WRN protein in the two knock-out lines was confirmed using immunoblot assays (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). We did not observe an effect of either single or concomitant knockdown of MLH1 and MSH3 on cell viability of the WRN-deficient SW480 cell lines (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>), despite efficacious depletion of the mRNAs encoding MLH1 and MSH3 (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). These results suggest that WRN dependence of MSI-H cancer cell lines might not be attributable to an acute and hard-wired synthetic lethal interaction between WRN and MLH1/MSH3.</p></sec><sec id="s2-3"><title>CRISPR-Cas9-mediated inactivation of WRN confirms the selective dependency of MSI-H CRC models on WRN</title><p>We carried out CRISPR-Cas9 depletion assays in MSS and MSI-H CRC models to independently confirm the selective WRN dependencies observed in shRNA/siRNA studies. Cell lines were stably transduced with Cas9 followed by transduction of lentiviral particles co-expressing GFP and single guide RNAs (sgRNAs) targeting WRN or the essential replication factor RPA3 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To investigate the relevance of the different protein domains in WRN by CRISPR scanning (<xref ref-type="bibr" rid="bib55">Shi et al., 2015</xref>), domain specific sgRNAs were used to target the exonuclease, helicase, RecQ helicase family DNA-binding (RQC) and Helicase and RNase D C-terminal (HRDC) domains and the C-terminal helix-turn-helix (HTH) motif. Negative selection of sgRNA expressing cells was monitored over 14 days via flow cytometry-based quantification of GFP expressing cells, and normalized to the effect of the RPA3 positive control sgRNA (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We did not observe depletion of cells harboring WRN targeting sgRNAs in the MSS CRC cell line HT-29. In contrast, MSI-H HCT 116 cells expressing WRN sgRNAs depleted to a similar level as observed for the RPA3 positive control. sgRNAs directed against the exonuclease, helicase and RQC domains were most effective, implying a functional or structural requirement of both these domains in the context of WRN dependency. Interestingly, strong depletion effects were also observed for sgRNAs targeting the C-terminal HTH motif (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). A similar WRN sgRNA depletion pattern was observed in the MSI-H CRC cell line RKO, while we found far less pronounced depletion effects in the MSS CRC model SK-CO-1 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In agreement with the RNAi studies, our CRISPR-Cas9 experiments suggest that WRN provides an essential gene function in two MSI-H CRC cell lines but not in two MSS CRC lines.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.008</object-id><label>Figure 3.</label><caption><title>CRISPR-Cas9-mediated knock-out of WRN confirms the selective dependency of MSI-H CRC models on WRN.</title><p>(<bold>A</bold>) Schematic representation of CRISPR-Cas9 depletion assays. Cas9 expressing cells were transduced with a lentivirus encoding GFP and sgRNAs. The percentage of GFP-positive cells was determined over time by flow cytometry. (<bold>B</bold>) Cas9 expressing MSS or MSI-H CRC cells were transduced with a lentivirus encoding GFP and sgRNAs targeting multiple domains in WRN as indicated. The percentage of GFP-positive cells was determined 14 days post-transduction and normalized to the fraction of GFP-positive cells at the first measurement. Depletion ratios are shown relative to the positive control RPA3 (n = 1 experimental replicate). Domains are annotated according to PFAM entry Q14191. RQC, RecQ helicase family DNA-binding domain; HRDC, Helicase and RNase D C-terminal, HTH, helix-turn-helix motif.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.009</object-id><label>Figure 3—figure supplement 1.</label><caption><title>CRISPR-Cas9-mediated knock-out of WRN confirms the selective dependency of MSI-H CRC models on WRN.</title><p>Cas9-GFP expressing MSS or MSI-H CRC cells were transduced with a lentivirus encoding GFP and sgRNAs targeting multiple domains in WRN as indicated. The percentage of GFP-positive cells was determined 14 days post-transduction and normalized to the fraction of GFP-positive cells at the first measurement. Depletion ratios are shown relative to the pan-essential positive control RPA3 (n = 1 experimental replicate). Domains are annotated according to PFAM entry Q14191. RQC, RecQ helicase family DNA-binding domain; HRDC, Helicase and RNase D C-terminal, HTH, helix-turn-helix motif.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>WRN dependency in MSI-H CRC is linked to its helicase function</title><p>To further dissect the relevance of WRN exonuclease and helicase function in WRN-dependent cell models, we generated FLAG-tagged, siRNA-resistant WRN (WRNr) expression constructs harboring loss-of-function mutations within the exonuclease- (E84A, Nuclease-dead) and helicase-domain (K577M, ATP-binding deficient), or both domains (E84A/K577M, Double-mutant) (<xref ref-type="bibr" rid="bib17">Gray et al., 1997</xref>; <xref ref-type="bibr" rid="bib22">Huang et al., 1998</xref>) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Wild-type and mutant forms of WRNr were transduced in HCT 116 cells and monoclonal lines with matched stable WRNr expression were generated. Expression and nuclear accumulation of transgenic WRNr variants among the cell lines was confirmed using immunofluorescence analysis (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Immunoblotting revealed that transgenic WRNr wild-type as well as the mutant WRN proteins were expressed at levels higher than the endogenous WRN counterpart (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Two wild-type WRNr expressing clones were selected based on the respective high and low expression of the transgene in order to cover the range of mutant WRNr variant expression observed in the selected panel of clones. As expected, viability of empty vector control-transduced cells was strongly reduced upon depletion of WRN (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Importantly, both the high and low expression level of wild-type WRNr was sufficient to render HCT 116 cells inert to knock-down of endogenous WRN (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). This demonstrates the on-target effect of the WRN siRNA duplex and indicates that the transgene-mediated rescue of WRN function is not protein level sensitive. Exogenous expression of the nuclease-dead form of WRNr almost completely rescued the effect of endogenous WRN depletion. In stark contrast, although expressed at similar or higher levels than WRNr wild-type, both the ATP-binding deficient and double-mutant form of WRNr were unable to restore viability following depletion of endogenous WRN (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In RKO cells expressing WRNr variants, we observed a slightly stronger dependency on WRN helicase ATP-binding function compared to exonuclease activity upon knock-down of endogenous WRN (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>), while WRNr-expressing monoclonal lines generated from the MSI endometrial carcinoma model HEC-265 showed an exclusive dependency on WRN helicase function (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), similar to HCT 116 cells. In summary, these results indicate that the ATP-binding activity of WRN and possibly its helicase function are crucial for the survival of MSI-H CRC cells.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.010</object-id><label>Figure 4.</label><caption><title>WRN dependency in MSI-H cancer cell lines is linked to its helicase function.</title><p>(<bold>A</bold>) Schematic representation of WRN domain structure. Location of nuclease- and ATPase-inactivating mutations in siRNA-resistant WRN (WRNr) expression constructs is indicated. (<bold>B</bold>) MSI-H CRC HCT 116 cells were stably transduced with FLAG-tagged wild-type or mutant forms of WRNr and monoclonal lines with similar WRNr expression levels were isolated. For WRNr wild-type, two clones with high and low transgene expression were selected to cover the expression range of WRNr variants. Anti-FLAG immunofluorescence analysis was performed to monitor homogenous expression of WRNr. Expression of WRNr wild-type and mutant forms and endogenous protein levels were determined using immunoblotting with anti-FLAG and anti-WRN antibodies. GAPDH expression was used to monitor equal loading. Scale bar, 20 µM. (<bold>C</bold>) WRNr-expressing HCT 116 cells were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to NTC siRNA. Data information: In (<bold>C</bold>), data are presented as mean ± SD of three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.011</object-id><label>Figure 4—figure supplement 1.</label><caption><title>WRN dependency in MSI-H cancer cell lines is linked to its helicase function.</title><p>(<bold>A</bold>) MSI-H CRC RKO cells were stably transduced with FLAG-tagged wild-type or mutant forms of WRNr. Anti-FLAG immunofluorescence analysis was performed to monitor homogenous expression of WRNr. Overexpression of WRNr wild-type and mutant forms compared to endogenous protein levels was determined using immunoblotting with anti-FLAG and anti-WRN antibodies. GAPDH expression was used to monitor equal loading. Scale bar, 20 µM. (<bold>B</bold>) WRNr-expressing RKO cells were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to NTC siRNA. (<bold>C</bold>) MSI-H endometrial carcinoma HEC-265 cells were stably transduced with FLAG-tagged wild-type or mutant forms of WRNr. WRNr-expressing HEC-265 cells were transfected with the indicated siRNAs. Cell viability was determined 7 days after transfection and is shown relative to NTC siRNA. Overexpression of WRNr wild-type and mutant forms compared to endogenous protein levels was determined using immunoblotting with anti-FLAG and anti-WRN antibodies. Actin expression was used to monitor equal loading. Data information: In (<bold>B</bold>) and <bold>C</bold>), data are presented as mean ± SD of three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Loss of WRN causes mitotic defects and nuclear abnormalities in MSI-H cells</title><p>In order to investigate the cellular basis for the viability reduction of MSI-H cancer cells upon WRN depletion, we monitored the consequences of WRN loss-of-function using immunofluorescence analysis of the nuclear membrane protein LAP2β and Hoechst DNA staining in MSS and MSI-H CRC cell lines. SW480 did not display any phenotypic differences upon transfection with NTC and WRN-targeting siRNAs (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Strikingly, in HCT 116 and RKO cells we observed formation of chromatin bridges and micronuclei upon WRN knock-down, both potential consequences of failed sister genome partitioning during mitosis (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Enlarged nuclei, indicative of failed mitosis, were additionally observed upon WRN knock-down in HCT 116 cells. Quantification of the frequency of chromatin bridges and micronuclei revealed that WRN depletion did not affect baseline levels of these aberrant nuclear morphologies in the MSS CRC cancer models SK-CO-1 and SW480, while the frequency of both chromatin bridges and micronuclei was strongly increased upon WRN knock-down in the MSI-H CRC cell lines HCT 116 and RKO (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). In non-transformed hTERT RPE-1 cells, WRN depletion led to a slight increase of chromatin bridge and micronucleus formation, although far less pronounced compared to the MSI-H CRC models (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Supportive of the immunofluorescence studies, live cell imaging revealed a strong increase of the incidence of lagging chromosomes and chromosome bridges during mitosis in WRN-depleted MSI-H CRC cell lines HCT 116 and RKO, but not in MSS SW480 cells (<xref ref-type="fig" rid="fig6">Figure 6</xref>). We conclude that WRN depletion in MSI-H cells results in nuclear morphology and integrity aberrations that are manifested during cell division. The correlation of these defects with the observed cell viability reduction in MSI-H models suggests that nuclear abnormalities are causally linked to the anti-proliferative effect of WRN loss.</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.012</object-id><label>Figure 5.</label><caption><title>WRN loss-of-function in MSI-H CRC results in nuclear morphology and integrity defects.</title><p>(<bold>A</bold>) MSS and MSI-H CRC cell lines were transfected with the indicated siRNAs. Immunofluorescence analysis was performed 96 hr after transfection to determine the fraction of cells with chromosomal bridges and micronuclei. Examples with enhanced brightness are shown as insets. LAP2β signal intensity was adjusted in a subset of samples for uniform representation. Scale bar, 10 µm. (<bold>B</bold>) Statistical analysis of chromosomal bridge phenotypes observed in siRNA knock-down studies in MSS and MSI-H CRC lines and hTERT RPE-1 non-transformed cells. (<bold>C</bold>) Statistical analysis of micronuclei phenotypes observed in siRNA knock-down studies in MSS and MSI-H CRC lines and hTERT RPE-1 non-transformed cells. Data information: In (<bold>B</bold> and <bold>C</bold>), data are presented as mean ± SD of two or three independent experiments (n ≥ 410 cells).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig5-v1.tif"/></fig><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.013</object-id><label>Figure 6.</label><caption><title>Time-lapse analysis of mitosis in WRN-depleted MSS and MSI-H CRC models.</title><p>Mitotic live cell imaging in WRN-depleted MSS and MSI-H CRC cell lines. Cells were transfected with WRN siRNA #1. Cells were stained with SiR-Hoechst dye and were analyzed 24 hr post siRNA transfection. Exemplary lagging chromosomes (arrowhead) and a chromatin bridge (asterisk) are designated. Duration of time-lapse is indicated in minutes. Scale bar, 5 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig6-v1.tif"/></fig></sec><sec id="s2-6"><title>Structural chromosome aberrations in MSI-H cells after WRN loss-of-function</title><p>The observed nuclear integrity and mitotic defects caused by WRN depletion in MSI-H cells could be the consequence of preceding genome maintenance aberrations. This hypothesis is reinforced by the important role of RECQ family helicases, including WRN, in genome integrity (<xref ref-type="bibr" rid="bib9">Chu and Hickson, 2009</xref>). To interrogate genome integrity, we performed mitotic chromosome spread analysis in MSI-H, MSS and non-transformed cells after depletion of WRN. To overcome the low abundance of mitotic cells in WRN-depleted MSI-H cell lines, caffeine was added to cultured cells to bypass the G2/M checkpoint. Strikingly, WRN loss elicited structural chromosome aberrations, such as chromosome breaks and non-homologous radial formations, in the MSI-H CRC cell lines HCT 116 and RKO (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Quantification of the number of chromatin breaks per karyotype demonstrated a strong increase in the fraction of cells harboring 1–5 or &gt;5 chromosome breaks in the two MSI-H CRC models upon WRN depletion (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). In the MSS CRC model SW480 and hTERT RPE-1 non-transformed cells only a minor increase of karyotypes with chromosome breaks was detected (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.014</object-id><label>Figure 7.</label><caption><title>Loss of WRN function in MSI-H CRC causes severe chromosomal defects.</title><p>(<bold>A</bold>) MSS and MSI-H CRC cell lines were transfected with the indicated siRNAs. Mitotic chromosome spreads were prepared 72 hr after transfection and visualized by microscopy. Non-homologous radial formations are designated by arrows, breaks are labeled with asterisks. (<bold>B</bold>) Quantification of chromosomal defects observed in siRNA knock-down studies in MSS and MSI-H CRC lines and hTERT RPE-1 non-transformed cells. The status of chromosomal breaks of individual metaphase spreads was categorized into normal, 1–5 breaks or more than five breaks (n ≥ 28 spreads of two independently analyzed slides). Non-homologous radial formation was counted as two breaks.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43333.015</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Elevated levels of the DNA damage marker γ-H2AX upon loss of WRN function in MSI-H CRC cells.</title><p>(<bold>A</bold>) MSS and MSI-H CRC cell lines were transfected with the indicated siRNAs or treated with 5 µM etoposide. Immunofluorescence analysis was performed 72 hr after transfection or 24 hr post etoposide treatment. (<bold>B</bold>) Quantitative analysis of γ-H2AX mean nuclear intensities upon siRNA-mediated knock-down of WRN or etoposide treatment in MSS and MSI-H CRC lines and hTERT RPE-1 non-transformed cells. Data information: In (<bold>B</bold>), individual values and mean of two independent experiments (n ≥ 140 cells) are presented.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43333-fig7-figsupp1-v1.tif"/></fig></fig-group><p>To test whether signs of DNA damage can already be detected in WRN-depleted interphase cells, we analyzed the intensity of nuclear γ-H2AX signals. We observed a strong induction of γ-H2AX upon siRNA-mediated depletion of WRN in MSI-H, but not MSS, CRC cancer cell lines (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Strikingly, in both HCT 116 and RKO MSI-H CRC lines, WRN depletion led to an increase in nuclear γ-H2AX signal similar to or higher than upon treatment of cells with the DNA double-strand break-inducing agent etoposide (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and B</xref>). Importantly, nuclear γ-H2AX levels in non-transformed and MSS hTERT RPE-1 cells were strongly increased by treatment with etoposide, while loss of WRN had no effect in this model (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>).</p><p>Our analyses suggest that WRN helicase is essential for maintaining genome integrity in MSI-H cells by preventing chromosome breaks and erroneous chromosome fusions. The observed mitotic chromosome aberrations in WRN-depleted MSI-H cells can also explain the aforementioned nuclear morphology and mitotic defects, including micronuclei, lagging chromosomes and chromatin bridges. The detection of DNA damage markers in interphase nuclei of WRN-depleted MSI-H cells suggests that the aforementioned mitotic and post-mitotic aberrations originate from genome integrity defects in interphase. The correlation of chromosome aberrations and nuclear abnormalities with MSI-H status following loss of WRN function indicate that genome integrity defects are responsible for the profound reduction in viability of MSI-H cancer cells.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Treatment paradigms for MSI-H tumors have recently shifted with the approval of the immune checkpoint agents pembrolizumab, nivolumab and ipilimumab, targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) in this patient segment (<xref ref-type="bibr" rid="bib36">Le et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Le et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Overman et al., 2018</xref>). Pembrolizumab constitutes the first cancer therapy approval based on a patient selection biomarker irrespective of the tumor type, highlighting MSI-H status as a therapeutically trackable and clinically implemented feature of tumor cells (<xref ref-type="bibr" rid="bib15">Goswami and Sharma, 2017</xref>). While responses to immune checkpoint blockade in MSI-H cancer are often durable, intrinsic and acquired resistance to immunotherapy represents a continuous medical need in MSI-H cancer.</p><p>The highest prevalence of MMR-deficiency/MSI-H status is observed among CRC, gastric and endometrial cancers (<xref ref-type="bibr" rid="bib10">Cortes-Ciriano et al., 2017</xref>). Recent genomic analyses have outlined a detailed landscape of genomic alterations in MSI-H tumors (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Network, 2012</xref>; <xref ref-type="bibr" rid="bib29">Knijnenburg et al., 2018</xref>). However, while MSI-H status is linked to a CpG island methylator (CIMP) phenotype and an increased mutational burden, a functional dependency enabling selective targeting of MSI-H cancer cells remains elusive. The results of this study uncover a novel vulnerability of MSI-H tumor cell models and indicate that pharmacological inhibition of WRN ATPase/helicase function might serve as an attractive targeted therapeutic strategy in MSI-H cancer.</p><p>Our data suggest that similar to the tumor agnostic activity of checkpoint blockade, MMR deficiency and MSI-H status represent a genetic determinant for WRN dependency regardless of tumor type. As indicated by the MLH1/MSH3 reconstitution and depletion studies, the genetic interaction of WRN and MMR genes cannot readily be recapitulated using isogenic cell models and thus seems to be distinct from acute and hard-wired synthetic lethal interactions, such as described in cancer cells for the alternate BAF complex ATPases SMARCA2/SMARCA4 or the cohesin subunits STAG1/STAG2 (<xref ref-type="bibr" rid="bib48">Oike et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">van der Lelij et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Benedetti et al., 2017</xref>). In the Random Forest model (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), loss of MLH1 expression was the feature most strongly associated with WRN dependency. However, we cannot rule out that alterations frequently co-occurring with MMR-deficiency or MSI-H status (<xref ref-type="bibr" rid="bib5">Boland and Goel, 2010</xref>; <xref ref-type="bibr" rid="bib29">Knijnenburg et al., 2018</xref>) alone or in combination contribute to the context-dependent requirement on WRN function in MSI-H cancer cell lines. Further work is required to decipher which specific or cumulative genetic alterations elicit WRN dependency in MMR-deficient and MSI-H cells.</p><p>Upon WRN loss-of-function we observe a strong and rapid decrease in the viability of MSI-H cell models that is accompanied by nuclear abnormalities and cell division defects. In particular, we find that WRN-depleted MSI-H cancer cells display chromosome breaks, chromatin bridges and micronuclei indicative of genome instability that is highlighted during cell division. The strong induction of γ-H2AX in WRN-depleted MSI-H interphase cells suggest that pervasive DNA damage, e. g. DNA double strand breaks, accumulate already in interphase prior to entry into mitosis. The occurrence of these defects and phenomena in MSI-H but not MSS cells upon WRN inactivation suggests that these aberrations might be causally linked to the selective reduction in viability in MSI-H cells. While rescue studies using WRN variants clearly indicate WRN helicase function as the critical enzymatic activity in MSI-H cell models, CRISPR domain scanning indicates a potential structural requirement of the exonuclease domain and the HTH loop of WRN.</p><p>WRN is a member of the RecQ helicase family which fulfils pleiotropic functions in DNA repair (<xref ref-type="bibr" rid="bib9">Chu and Hickson, 2009</xref>). MMR activity is required for activation of the G2/M checkpoint in response to DNA damage prior to entry into mitosis (<xref ref-type="bibr" rid="bib47">O'Brien and Brown, 2006</xref>). WRN function in MSI-H cells might therefore be critical for the resolution of DNA damage events and to prevent premature entry into mitosis. Of note, cell lines derived from Werner syndrome patients display defective mitotic recombination and are susceptible to genome instability (<xref ref-type="bibr" rid="bib51">Prince et al., 2001</xref>). However, in MSS cancer and non-transformed cells WRN depletion had no or very mild effects on viability, suggesting that pharmacological inhibition of WRN might allow for an MSI-H cancer-directed therapy that spares normal cells and tissues.</p><p>The chromosome breaks and radial chromosomes observed in MSI-H cells upon WRN depletion indicate the generation and/or persistence of DNA double strand breaks. Future research is required to dissect the molecular basis for this effect. It is conceivable that WRN is required to process and resolve DNA repair or replication intermediates that arise in MMR-deficient cells or that MMR is required to cope with intermediates emerging upon compromised WRN function. The identification of the molecular basis of the WRN-MSI-H relationship will also help to understand why some rare outlier MSI-H cell lines (see <xref ref-type="fig" rid="fig1">Figure 1B</xref>) do not respond to WRN inactivation.</p><p>Werner syndrome patients show an increased lifetime risk to develop tumors, pointing to a tumor-suppressive function of WRN (<xref ref-type="bibr" rid="bib16">Goto et al., 2013</xref>). Interestingly, homozygous <italic>Wrn</italic>-null mice display no overt phenotype and do not recapitulate the premature ageing or cancer predisposition conditions of Werner syndrome, unless crossed into a <italic>Terc</italic>-null background (<xref ref-type="bibr" rid="bib8">Chang et al., 2004</xref>; <xref ref-type="bibr" rid="bib37">Lebel and Leder, 1998</xref>; <xref ref-type="bibr" rid="bib38">Lombard et al., 2000</xref>). Mutations in Werner syndrome are almost exclusively truncating nonsense, splicing or frameshift mutations affecting WRN nuclear localization, suggesting that concomitant loss of WRN helicase and exonuclease function might be required for the onset of Werner syndrome (<xref ref-type="bibr" rid="bib14">Fu et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2006</xref>; <xref ref-type="bibr" rid="bib43">Matsumoto et al., 1997</xref>; <xref ref-type="bibr" rid="bib59">Yokote et al., 2017</xref>). This indicates that inhibition of WRN helicase function might have a therapeutic index for the treatment of MSI-H cancer without inducing Werner syndrome related phenotypes.</p><p>Our study highlights the power of combining deep functional genomic screening data with tumor cell line profiling to identify new targets with an associated predictive biomarker in oncology. Given the possibility to develop potent and selective small molecule inhibitors of WRN helicase (<xref ref-type="bibr" rid="bib2">Aggarwal et al., 2013</xref>; <xref ref-type="bibr" rid="bib1">Aggarwal et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Rosenthal et al., 2010</xref>), our findings outline a novel strategy for the treatment of a clinically defined subset of patients harboring MSI-H/MMR-deficient tumors. Since genome instability can elicit cytoplasmic nucleic acid sensor pathways and innate immune responses (<xref ref-type="bibr" rid="bib42">Mackenzie et al., 2017</xref>), the induction of cancer cell selective nuclear aberrations by WRN inactivation could provide a synergistic combination option with the approved immunotherapy agents for the benefit of MSI-H cancer patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Gene <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">Werner Syndrome <break/>RecQ Like Helicase (WRN)</td><td valign="top">N/A</td><td valign="top">Entrez Gene: 7486</td><td valign="top"/></tr><tr><td valign="top">Genetic reagent <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">NTC siRNA</td><td valign="top">Dharmacon</td><td valign="top">D-001810–10</td><td valign="top">non-targeting <break/>siRNA pool</td></tr><tr><td valign="top">Genetic reagent <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">WRN siRNA pool</td><td valign="top">Dharmacon</td><td valign="top">L-010378–00</td><td valign="top">WRN-targeting <break/>siRNA pool</td></tr><tr><td valign="top">Genetic reagent <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">WRN siRNA</td><td valign="top">Dharmacon</td><td valign="top">J-010378–05</td><td valign="top">WRN-targeting <break/>siRNA</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">HCT 116</td><td valign="top">ATCC</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0291">CVCL_0291</ext-link></td><td valign="top">MSI-H CRC cell line</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">RKO</td><td valign="top">ATCC</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0504">CVCL_0504</ext-link></td><td valign="top">MSI-H CRC cell line</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">SW480</td><td valign="top">ATCC</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0546">CVCL_0546</ext-link></td><td valign="top">MSS CRC cell line</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">SK-CO-1</td><td valign="top">ATCC</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0626">CVCL_0626</ext-link></td><td valign="top">MSS CRC cell line</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">hTERT RPE-1</td><td valign="top">ATCC</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_4388">CVCL_4388</ext-link></td><td valign="top">Non-transformed <break/>telomerase immortalized <break/>cell line</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse anti-WRN</td><td valign="top">Cell Signaling</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10692114">AB_10692114</ext-link></td><td valign="top">1/1000 dilution for <break/>immunoblot</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse anti-GAPDH</td><td valign="top">Abcam</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2107448">AB_2107448</ext-link></td><td valign="top">1/30000 dilution for <break/>immunoblot</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse anti-FLAG</td><td valign="top">SIGMA</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_262044">AB_262044</ext-link></td><td valign="top">1/1000 dilution for <break/>immunoblot</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse anti-LAP2ß</td><td valign="top">BD Transduction <break/>Laboratories</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_398313">AB_398313</ext-link></td><td valign="top">1/100 for <break/>immunofluorescence <break/>analysis</td></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pLVX-WRN-3x <break/>FLAG-IRES-Puro</td><td valign="top">This study</td><td valign="top"/><td valign="top">Lentiviral vector for <break/>stable expression of <break/>WRN wild-type</td></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pLVX-WRN-3x <break/>FLAG-IRES-Puro E84A</td><td valign="top">This study</td><td valign="top"/><td valign="top">Lentiviral vector <break/>for stable expression <break/>of WRN E84A mutant</td></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pLVX-WRN-3x <break/>FLAG-IRES-Puro K577M</td><td valign="top">This study</td><td valign="top"/><td valign="top">Lentiviral vector for <break/>stable expression of <break/>WRN K577M mutant</td></tr><tr><td valign="top">Recombinant <break/>DNA reagent</td><td valign="top">pLVX-WRN-3x <break/>FLAG-IRES-Puro E84A _K577M</td><td valign="top">This study</td><td valign="top"/><td valign="top">Lentiviral vector for <break/>stable expression of <break/>WRN E84A/K577M <break/>double mutant</td></tr><tr><td valign="top">Other</td><td valign="top">Drive database</td><td valign="top">PMID 28753431</td><td valign="top"/><td valign="top">Functional genomics <break/>database on cancer <break/>cell line dependencies</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Random Forest model</title><p>To explore the hypothesis that WRN sensitivity is associated with MSI, we employed an exploratory machine learning approach (<xref ref-type="bibr" rid="bib52">Qi, 2012</xref>). We first divided the DRIVE WRN cell line sensitivity data (<xref ref-type="bibr" rid="bib44">McDonald et al., 2017</xref>) into four distinct groups, using a k-means clustering algorithm. We chose four clusters to model insensitive (cluster 1), moderate insensitive (cluster 2), moderate sensitive (cluster 3) and sensitive (cluster 4) cell lines. We subsequently denoted clusters 1 and 2 as insensitive and clusters 3 and 4 as sensitive and chose an RSA score &lt;−1.37 (maximum value of cluster 3) as a cutoff between sensitive and insensitive lines. Only a small fraction of cell lines, 30 out of 371 cell lines (8%), is sensitive in the entire data set, suggesting a pronounced class imbalance between sensitive and insensitive cell lines. To address this class imbalance, we focused our subsequent analysis on cell lines originating from CRC, as i) most sensitive cell lines are from this indication and ii) MSI has been extensively characterized in this indication (<xref ref-type="bibr" rid="bib5">Boland and Goel, 2010</xref>; <xref ref-type="bibr" rid="bib45">Medico et al., 2015</xref>). 36% (13 out of 36) of colon cancer cell lines are sensitive to WRN loss of function according to our k-means clustering based approach.</p><p>We next assembled a MSI feature list. We used cell line gene expression and mutation data for the cell lines from a set of genes, i) involved in MMR (EXO1, MLH1, MLH3, MSH2, MSH3, MSH6) and ii) genetic target genes of MSI in CRC (<xref ref-type="bibr" rid="bib5">Boland and Goel, 2010</xref>). We next trained a Random Forest model based on 50% of the data. On the full dataset, the model classifies WRN sensitive and insensitive cell lines with an accuracy of 0.89 and a recall rate for sensitive lines of 0.69.</p></sec><sec id="s4-2"><title>MSI analysis</title><p>Genomic DNA was isolated using QIAampDNA mini kit (Qiagen, Hilden, Germany). Per reaction 2 ng of genomic DNA was used for fluorescent PCR-based analysis of the mononucleotide microsatellite marker length using the Promega MSI Analysis System, Version 1.2 kit. Microsatellite fragment length of a standard panel of markers (NR-21, BAT-26, BAT-25, NR-24 and MONO-27) according to the ‘Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability’ (<xref ref-type="bibr" rid="bib57">Umar et al., 2004</xref>) was analyzed using capillary electrophoreses (Applied Biosystems 3130xl Genetic Analyzer, 16-capillary electrophoresis instrument) and evaluated with GeneMapper Software 5 (Applied Biosystems).</p></sec><sec id="s4-3"><title>Cell culture and lentiviral transduction</title><p>HCT 116 cells were cultured in McCoy’s 5A medium (GIBCO, 36600–021) with glutamax supplemented with 10% fetal calf serum (FCS), hTERT RPE-1 cells were cultured in DMEM:F12 (ATCC, 30–2006) supplemented with 10% FCS and 0.01 mg/ml Hygromycin B. RKO, SW480, CaCo-2 and SK-CO-1 cells were cultured in EMEM (SIGMA, M5650) with glutamax supplemented with 10% FCS and Na-Pyruvate. SNU-C4 cells were cultured in RPMI1640 medium (ATCC, 30–2001) with glutamax, supplemented with 10% FCS, 25 mM HEPES and 25 mM NaHCO3. LS1034 cells were cultured in RPMI-1640 (ATCC, 30–2001) supplemented with 10% FCS. MFE-280 cells were cultured in 40% RPMI 1640 (GIBCO, 61870-010), 40% DMEM (SIGMA, D6429) supplemented with 20% FCS and 1X insulin-transferrin-sodium selenite (GIBCO, 41400–045). HEC-265 cells were cultured in EMEM (SIGMA, M5650) with glutamax supplemented with 15% FCS. ISHIKAWA cells were cultured in EMEM (SIGMA, M5650) with glutamax medium supplemented with 5% FCS and NEAA. HEC-6 cells were cultured in EMEM (SIGMA, M5650) with glutamax supplemented with 15% FCS, NEAA and Na-Pyruvate. HT-29_CRISPR-Cas9 cells were cultured in McCoy’s 5A (GIBCO, 36600–021) with glutamax supplemented with 10% FCS and 10 µg/ml Blasticidin (Invitrogen, R210-01). HCT 116_CRISPR-Cas9 cells were cultured like the parental cell line but supplemented with 2 µg/ml Puromycin. All supplements were obtained from GIBCO, FCS (SH30071.03) from GE Healthcare Life Sciences and Puromycin from SIGMA (P9620). Lentiviral particles were produced using the Lenti-X Single Shot system (Clontech, Mountain View, CA, US). Following lentiviral infection, stably transduced pools were generated using Puromycin selection (HCT 116: 2 µg/ml, RKO: 0.5 µg/ml, SK-CO-1: 1 µg/ml) or Blasticidin (HT-29: 10 µg/ml). Sources, MSI status and authentication information (STR fingerprinting at Eurofins Genomics, Germany) of cell lines used in this study are provided in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. All cell lines were tested negatively for mycoplasma contamination and have been authenticated by STR fingerprinting (HCT 116 + ch2, HCT 116 + ch3, HCT 116 + ch3+ch5 and subclones generated from SW480 were not analyzed by STR fingerprinting).</p></sec><sec id="s4-4"><title>siRNA transfection and cell viability</title><p>For knock-down experiments, cells were transfected with ON-TARGETplus SMARTpool siRNA duplexes (Dharmacon, Lafayette, CO, US) targeting WRN (L-010378–00), MLH1 (L-003906–00) or MSH3 (L-019665–00) using Lipofectamine RNAiMAX reagent according to the manufacturer’s instructions (Invitrogen, Waltham, MA, US). For WRN knock-down, additionally an individual siRNA was used (J-010378–05). Chromosome spreads, immunoblotting, immunofluorescence and live cell imaging experiments were performed using a final siRNA concentration of 20 nM. Cell viability assays were performed using 10 nM siRNA in 96-well plates in a total volume of 100 µl per well. Viability was determined using CellTiter-Glo (Promega, Madison, WI, US). Seven days post-transfection, 100 µl CellTiter-Glo solution was added directly to the cell medium, mixed and incubated for 10 min prior to determination of the luminescence signal. Crystal violet staining was performed in 24-well format using a total volume of 1000 µl per well. Seven days post-transfection, cells were fixed with 4% formaldehyde in PBS and stained twice for 30 min with crystal violet (SIGMA, HT901). For co-depletion of p53 and WRN 10 nM of the respective siRNA duplexes each were used for immunoblot and viability assay.</p></sec><sec id="s4-5"><title>Cell extracts for immunoblotting</title><p>Cell pellets were resuspended in extraction buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Nonidet P-40 supplemented with Complete protease inhibitor mix [Roche, Switzerland] and Phosphatase inhibitor cocktails [SIGMA, P5726 and P0044]).</p></sec><sec id="s4-6"><title>Antibodies</title><p>The following antibodies were used: WRN (8H3) mouse mAb (Cell Signaling, 4666, 1/1000 dilution), mouse anti-GAPDH (Abcam, ab8245, 1/30000 dilution), mouse anti-FLAG (SIGMA, F1804, 1/1000 [immunoblot] or 1/500 [immunofluorescence] dilution), mouse anti-LAP2ß (BD Transduction Laboratories #611000, 1/100 dilution), mouse anti-p53 (Calbiochem, OP43, 1/1000 dilution), rabbit anti-Actin (SIGMA, A2066, 1/4000) dilution), mouse anti-MLH1 (Cell Signaling, 3515, 1/1000 dilution), rabbit anti phospho-Histone H2A.X (Ser139) (Cell Signaling, 2577, 1/800 dilution) a rabbit anti-MSH3 (Santa Cruz, sc-11441, 1/500 dilution) and secondary rabbit (Dako, P0448, 1/1000 dilution), mouse anti-IgG-HRP (Dako, P0161, 1/1000 dilution) and mouse Alexa Fluor 488 (Molecular Probes, Eugene, OR, US, 1/1000 dilution).</p></sec><sec id="s4-7"><title>Quantitative reverse transcription PCR (qRT-PCR)</title><p>RNA was isolated 472 hr post-transfection and reversely transcribed using SuperScript VILO kit (Thermo Scientific). All qPCR analyses were performed with the QuantiTect Multiplex PCR kit (Qiagen, Hilden, Germany) on a StepOne Real-Time PCR Sytem (Applied Biosytems) with a total of 45 cycles. Constitutive maintenance gene 18S rRNA (Applied Biosystems, Quencher VIC/MGB, 4319413E) and human WRN (Applied Biosystems, Quencher FAM/MGB-NFQ, 4331182), human MLH1 (Applied Biosystems, Quencher FAM/MGB-NFQ, 4453320) and human MSH3 (Applied Biosystems, Quencher FAM/MGB-NFQ, 4448892) TaqMan probes were used. WRN expression was normalized to 18S rRNA expression levels and is indicated relative to the NTC control.</p></sec><sec id="s4-8"><title>CRISPR-Cas9-mediated gene knock-out</title><p>To introduce mutations in WRN in SW480, the following sgRNA sequences were cloned into pSpCas9 BB-2A-GFP pX458 (GenScript, China): GGCCACCATTATACAATAGA (EN-domain_01), GCAGTTAAAAAGGCAGGTGT (EN-domain_02) and GTCTTGCCGATCAATATCGC (RQ-domain_01). Cells were transfected with X-tremeGENE 9 DNA Transfection Reagent (SIGMA, 6365779001), sorted after 48 hr for GFP positive cells and diluted to obtain single cell clones. WRN knock-out was monitored by immunoblotting.</p></sec><sec id="s4-9"><title>CRISPR depletion assays</title><p>Stable Cas9 expressing cell lines, using either Blasticidin or Puromycin as selection markers, were transduced with vectors encoding GFP and sgRNAs targeting different domains of WRN (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). On day three post-transfection the fraction of GFP positive cells, measured via flow cytometry analysis, was set to 100%. All values were normalized to the control RPA3_1.3 for relative depletion ratio.</p></sec><sec id="s4-10"><title>cDNA transgene vectors </title><p>pLVX-WRN-3xFLAG-IRES-Puro, pLVX-WRN-3xFLAG-IRES-Puro K577M, pLVX-WRN-3xFLAG-IRES-Puro E84A and pLVX-WRN-3xFLAG-IRES-Puro E84A _K577M for siRNA-resistant transgene expression were generated by gene synthesis (GenScript, China) based on the WRN cDNA sequence NCBI NM_000553.5 followed by cloning into the parental pLVX vector (Clontech, Mountain View, CA, US). Codon optimization changes were introduced into WRN coding sequences to render the transgenes siRNA-resistant.</p></sec><sec id="s4-11"><title>Immunofluorescence</title><p>For immunofluorescence, 72 hr post siRNA transfection cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100 in PBS for 10 min and blocked with 3% BSA in PBS containing 0.01% Triton X-100. Cells were incubated with primary LAP2ß or phospho-Histone H2A.X (Ser139) and secondary antibody (Alexa 488, Molecular Probes, Eugene, OR, US), DNA was counterstained with Hoechst 33342 (Molecular Probes, Eugene, OR, US; H3570). Coverslips and chambers were mounted with ProLong Gold (Molecular Probes, Eugene, OR, US). Images were taken with an Axio Plan2/AxioCam microscope and processed with MrC5/Axiovision software (Zeiss, Germany). For quantification of γ-H2AX immunofluorescence, nuclei were identified based on Hoechst staining using segmentation in ImageJ 1.52a and corresponding γ-H2AX mean intensities of nuclei were determined.</p><sec id="s4-11-1"><title>Chromosome spreads and live-cell imaging</title><p>For chromosome spread analysis, Nocodazole (1.5 µM final concentration) and 2 mM caffeine was added to the medium for 6 hr. Cells were harvested and hypotonically swollen in 40% medium/60% tap water for 5 min at room temperature. Cells were fixed with freshly made Carnoy’s solution (75% methanol, 25% acetic acid), and the fixative was changed three times. For spreading, cells in Carnoy’s solution were dropped onto glass slides and dried. Slides were stained with 5% Giemsa (Merck) for 4 min, washed briefly in tap water and air dried. For chromosome spread analysis two independent slides were scored blindly for each condition. Live-cell imaging was performed using Spinning Disk Confocal UltraView Vox Axio Observer equipped with Plan apochromat 20x/0.8 objective (Zeiss) and an electron-multiplying charge-coupled device 9100–13 camera (Hamamatsu Photonics). The microscope was controlled using Volocity software (Perkin-Elmer). DNA was counterstained with 100 nM SiR-Hoechst 3 hr before the start of imaging. At 24 hr post siRNA transfection cell nuclei were imaged in 2 z slice sections spaced 6 μm every 6 min for 48 hr. For the imaging, cells were seeded into glass bottom 24 well SensoPlate (Greiner) with imaging medium (phenol red free DMEM supplemented with 10% [vol/vol] FCS, L-glutamine 2 mM and 1% [vol/vol] penicillin-streptomycin). During live cell imaging, cells were maintained at 37°C in a humidified 5% CO<sub>2</sub> atmosphere.</p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We would like to thank Susanne Stockinger, Vanessa Rössler, Jodie Grant and Christoph Reiser (all Boehringer Ingelheim RCV GmbH) for generation of Cas9-expressing cell lines and Thomas Lendl (Institute of Molecular Pathology, Austria) for the support of immunofluorescence quantification analysis. We are grateful to Christoph Gasche (Medical University of Vienna) for providing the MSH3 antibody and Stephen West (The Francis Crick Institute, UK) for helpful suggestions and advice. The Research Institute of Molecular Pathology (IMP) is supported by Boehringer Ingelheim. Research in the laboratory of JMP is funded by Boehringer Ingelheim and grants by the Austrian Research Promotion Agency (FFG 834223, FFG 852936) and the European Research Council H2020 (693949). KN is supported by an EMBO Long Term Fellowship (ALTF 1335–2016) and a HFSP fellowship (LT001527/2017). PVDL is a member of the Boehringer Ingelheim Discovery Research global post-doc program.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf2"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf3"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf4"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf5"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf6"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf7"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf8"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf9"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf10"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf11"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf12"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf13"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf14"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf15"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn><fn fn-type="COI-statement" id="conf16"><p>Full-time employee of Boehringer Ingelheim RCV GmbH &amp; Co KG, Vienna, Austria</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Validation, Investigation, Visualization, Methodology, Writing—original draft</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Visualization, Methodology, Writing—original draft</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Visualization, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Validation, Investigation, Visualization, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con6"><p>Validation, Investigation, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Software, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Software, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Software, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Software, Formal analysis, Validation, Investigation, Visualization, Writing—original draft</p></fn><fn fn-type="con" id="con11"><p>Validation, Investigation, Visualization, Writing—original draft</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Visualization, Writing—original draft</p></fn><fn fn-type="con" id="con16"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con17"><p>Supervision, Funding acquisition, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con18"><p>Supervision, Funding acquisition, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Supervision, Validation, Visualization, Methodology, Writing—original draft, Project administration</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Supervision, Validation, Visualization, Methodology, Writing—original draft, Project administration</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.43333.016</object-id><label>Supplementary file 1.</label><caption><title>MSS/MSI-H status analysis of CRC, endometrial and gastric carcinoma cell lines.</title><p>MSS/MSI-H status was analyzed using fluorescent PCR-based analysis of the mononucleotide microsatellite markers NR-21, BAT-26, BAT-25, NR-24 and MONO-27. Main peak sizes for the mononucleotide microsatellite markers are shown for the MSS control cell line K562 and CRC, endometrial and gastric carcinoma cell lines. Cell models were classified as MSS (blue) or MSI-H (red) according to the indicated size range classification of MSS alleles.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-43333-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.43333.017</object-id><label>Supplementary file 2.</label><caption><title>Overview of cell lines used in this study.</title><p>Cell lines used in this study are listed with tumor type of origin, MSS/MSI-H status, vendor source, and STR confirmation status. Variable STR profiles are reported for ISHIKAWA cells, consistent with MSI-H status (<xref ref-type="bibr" rid="bib31">Korch et al., 2012</xref>).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-43333-supp2-v1.docx"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.43333.018</object-id><label>Supplementary file 3.</label><caption><title>Sequences of sgRNAs used for CRISPR depletion studies.</title><p>Sequences of sgRNAs used for targeting WRN are listed in N- to C-terminal order according to the representation in <xref ref-type="fig" rid="fig3">Figure 3</xref> and Expanded View <xref ref-type="fig" rid="fig3">Figure 3</xref>. Domains are annotated according to PFAM entry Q14191. RQC, RecQ helicase family DNA-binding domain; HRDC, Helicase and RNase D C-terminal, HTH, helix-turn-helix motif. Negative and positive control sgRNA sequences are also listed.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-43333-supp3-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.43333.019</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-43333-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname> <given-names>M</given-names></name><name><surname>Sommers</surname> <given-names>JA</given-names></name><name><surname>Shoemaker</surname> <given-names>RH</given-names></name><name><surname>Brosh</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inhibition of helicase activity by a small molecule impairs werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress</article-title><source>PNAS</source><volume>108</volume><fpage>1525</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1073/pnas.1006423108</pub-id><pub-id pub-id-type="pmid">21220316</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname> <given-names>M</given-names></name><name><surname>Banerjee</surname> <given-names>T</given-names></name><name><surname>Sommers</surname> <given-names>JA</given-names></name><name><surname>Iannascoli</surname> <given-names>C</given-names></name><name><surname>Pichierri</surname> <given-names>P</given-names></name><name><surname>Shoemaker</surname> <given-names>RH</given-names></name><name><surname>Brosh</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway</article-title><source>Cancer Research</source><volume>73</volume><fpage>5497</fpage><lpage>5507</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2975</pub-id><pub-id pub-id-type="pmid">23867477</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Caponigro</surname> <given-names>G</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Venkatesan</surname> <given-names>K</given-names></name><name><surname>Margolin</surname> <given-names>AA</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Wilson</surname> <given-names>CJ</given-names></name><name><surname>Lehár</surname> <given-names>J</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Sonkin</surname> <given-names>D</given-names></name><name><surname>Reddy</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Murray</surname> <given-names>L</given-names></name><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Monahan</surname> <given-names>JE</given-names></name><name><surname>Morais</surname> <given-names>P</given-names></name><name><surname>Meltzer</surname> <given-names>J</given-names></name><name><surname>Korejwa</surname> <given-names>A</given-names></name><name><surname>Jané-Valbuena</surname> <given-names>J</given-names></name><name><surname>Mapa</surname> <given-names>FA</given-names></name><name><surname>Thibault</surname> <given-names>J</given-names></name><name><surname>Bric-Furlong</surname> <given-names>E</given-names></name><name><surname>Raman</surname> <given-names>P</given-names></name><name><surname>Shipway</surname> <given-names>A</given-names></name><name><surname>Engels</surname> <given-names>IH</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>GK</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Aspesi</surname> <given-names>P</given-names></name><name><surname>de Silva</surname> <given-names>M</given-names></name><name><surname>Jagtap</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Palescandolo</surname> <given-names>E</given-names></name><name><surname>Gupta</surname> <given-names>S</given-names></name><name><surname>Mahan</surname> <given-names>S</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>MacConaill</surname> <given-names>L</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Reich</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Chan</surname> <given-names>V</given-names></name><name><surname>Myer</surname> <given-names>VE</given-names></name><name><surname>Weber</surname> <given-names>BL</given-names></name><name><surname>Porter</surname> <given-names>J</given-names></name><name><surname>Warmuth</surname> <given-names>M</given-names></name><name><surname>Finan</surname> <given-names>P</given-names></name><name><surname>Harris</surname> <given-names>JL</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Morrissey</surname> <given-names>MP</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Schlegel</surname> <given-names>R</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title><source>Nature</source><volume>483</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature11003</pub-id><pub-id pub-id-type="pmid">22460905</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti</surname> <given-names>L</given-names></name><name><surname>Cereda</surname> <given-names>M</given-names></name><name><surname>Monteverde</surname> <given-names>L</given-names></name><name><surname>Desai</surname> <given-names>N</given-names></name><name><surname>Ciccarelli</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1</article-title><source>Oncotarget</source><volume>8</volume><fpage>37619</fpage><lpage>37632</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16838</pub-id><pub-id pub-id-type="pmid">28430577</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname> <given-names>CR</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Microsatellite instability in colorectal cancer</article-title><source>Gastroenterology</source><volume>138</volume><fpage>2073</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.12.064</pub-id><pub-id pub-id-type="pmid">20420947</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosh</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DNA helicases involved in DNA repair and their roles in cancer</article-title><source>Nature Reviews Cancer</source><volume>13</volume><fpage>542</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/nrc3560</pub-id><pub-id pub-id-type="pmid">23842644</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Network</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title><source>Nature</source><volume>487</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature11252</pub-id><pub-id pub-id-type="pmid">22810696</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>S</given-names></name><name><surname>Multani</surname> <given-names>AS</given-names></name><name><surname>Cabrera</surname> <given-names>NG</given-names></name><name><surname>Naylor</surname> <given-names>ML</given-names></name><name><surname>Laud</surname> <given-names>P</given-names></name><name><surname>Lombard</surname> <given-names>D</given-names></name><name><surname>Pathak</surname> <given-names>S</given-names></name><name><surname>Guarente</surname> <given-names>L</given-names></name><name><surname>DePinho</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Essential role of limiting telomeres in the pathogenesis of werner syndrome</article-title><source>Nature Genetics</source><volume>36</volume><fpage>877</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1038/ng1389</pub-id><pub-id pub-id-type="pmid">15235603</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname> <given-names>WK</given-names></name><name><surname>Hickson</surname> <given-names>ID</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>RecQ helicases: multifunctional genome caretakers</article-title><source>Nature Reviews Cancer</source><volume>9</volume><fpage>644</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/nrc2682</pub-id><pub-id pub-id-type="pmid">19657341</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes-Ciriano</surname> <given-names>I</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>WY</given-names></name><name><surname>Kim</surname> <given-names>TM</given-names></name><name><surname>Park</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A molecular portrait of microsatellite instability across multiple cancers</article-title><source>Nature Communications</source><volume>8</volume><fpage>15180</fpage><pub-id pub-id-type="doi">10.1038/ncomms15180</pub-id><pub-id pub-id-type="pmid">28585546</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croteau</surname> <given-names>DL</given-names></name><name><surname>Popuri</surname> <given-names>V</given-names></name><name><surname>Opresko</surname> <given-names>PL</given-names></name><name><surname>Bohr</surname> <given-names>VA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human RecQ helicases in DNA repair, recombination, and replication</article-title><source>Annual Review of Biochemistry</source><volume>83</volume><fpage>519</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035428</pub-id><pub-id pub-id-type="pmid">24606147</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname> <given-names>JM</given-names></name><name><surname>Christensen</surname> <given-names>ER</given-names></name><name><surname>Tester</surname> <given-names>DJ</given-names></name><name><surname>Kim</surname> <given-names>CY</given-names></name><name><surname>Roche</surname> <given-names>PC</given-names></name><name><surname>Burgart</surname> <given-names>LJ</given-names></name><name><surname>Thibodeau</surname> <given-names>SN</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability</article-title><source>Cancer Research</source><volume>58</volume><fpage>3455</fpage><lpage>3460</lpage><pub-id pub-id-type="pmid">9699680</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellegren</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Microsatellites: simple sequences with complex evolution</article-title><source>Nature Reviews Genetics</source><volume>5</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1038/nrg1348</pub-id><pub-id pub-id-type="pmid">15153996</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname> <given-names>W</given-names></name><name><surname>Ligabue</surname> <given-names>A</given-names></name><name><surname>Rogers</surname> <given-names>KJ</given-names></name><name><surname>Akey</surname> <given-names>JM</given-names></name><name><surname>Monnat</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human RECQ Helicase Pathogenic Variants, Population Variation and &quot;Missing&quot; Diseases</article-title><source>Human Mutation</source><volume>38</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1002/humu.23148</pub-id><pub-id pub-id-type="pmid">27859906</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname> <given-names>S</given-names></name><name><surname>Sharma</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic biomarker for cancer immunotherapy</article-title><source>Science</source><volume>357</volume><elocation-id>358</elocation-id><pub-id pub-id-type="doi">10.1126/science.aao1894</pub-id><pub-id pub-id-type="pmid">28751597</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname> <given-names>M</given-names></name><name><surname>Ishikawa</surname> <given-names>Y</given-names></name><name><surname>Sugimoto</surname> <given-names>M</given-names></name><name><surname>Furuichi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Werner Syndrome: a changing pattern of clinical manifestations in japan (1917~2008)</article-title><source>BioScience Trends</source><volume>7</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.5582/bst.2013.v7.1.13</pub-id><pub-id pub-id-type="pmid">23524889</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname> <given-names>MD</given-names></name><name><surname>Shen</surname> <given-names>JC</given-names></name><name><surname>Kamath-Loeb</surname> <given-names>AS</given-names></name><name><surname>Blank</surname> <given-names>A</given-names></name><name><surname>Sopher</surname> <given-names>BL</given-names></name><name><surname>Martin</surname> <given-names>GM</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name><name><surname>Loeb</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The Werner syndrome protein is a DNA helicase</article-title><source>Nature Genetics</source><volume>17</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/ng0997-100</pub-id><pub-id pub-id-type="pmid">9288107</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname> <given-names>H</given-names></name><name><surname>Frankel</surname> <given-names>WL</given-names></name><name><surname>Martin</surname> <given-names>E</given-names></name><name><surname>Arnold</surname> <given-names>M</given-names></name><name><surname>Khanduja</surname> <given-names>K</given-names></name><name><surname>Kuebler</surname> <given-names>P</given-names></name><name><surname>Nakagawa</surname> <given-names>H</given-names></name><name><surname>Sotamaa</surname> <given-names>K</given-names></name><name><surname>Prior</surname> <given-names>TW</given-names></name><name><surname>Westman</surname> <given-names>J</given-names></name><name><surname>Panescu</surname> <given-names>J</given-names></name><name><surname>Fix</surname> <given-names>D</given-names></name><name><surname>Lockman</surname> <given-names>J</given-names></name><name><surname>Comeras</surname> <given-names>I</given-names></name><name><surname>de la Chapelle</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)</article-title><source>New England Journal of Medicine</source><volume>352</volume><fpage>1851</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043146</pub-id><pub-id pub-id-type="pmid">15872200</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haugen</surname> <given-names>AC</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name><name><surname>Yamada</surname> <given-names>K</given-names></name><name><surname>Marra</surname> <given-names>G</given-names></name><name><surname>Nguyen</surname> <given-names>TP</given-names></name><name><surname>Nagasaka</surname> <given-names>T</given-names></name><name><surname>Kanazawa</surname> <given-names>S</given-names></name><name><surname>Koike</surname> <given-names>J</given-names></name><name><surname>Kikuchi</surname> <given-names>Y</given-names></name><name><surname>Zhong</surname> <given-names>X</given-names></name><name><surname>Arita</surname> <given-names>M</given-names></name><name><surname>Shibuya</surname> <given-names>K</given-names></name><name><surname>Oshimura</surname> <given-names>M</given-names></name><name><surname>Hemmi</surname> <given-names>H</given-names></name><name><surname>Boland</surname> <given-names>CR</given-names></name><name><surname>Koi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>8465</fpage><lpage>8472</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0002</pub-id><pub-id pub-id-type="pmid">18922920</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname> <given-names>JG</given-names></name><name><surname>Umar</surname> <given-names>A</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name><name><surname>Graff</surname> <given-names>JR</given-names></name><name><surname>Ahuja</surname> <given-names>N</given-names></name><name><surname>Issa</surname> <given-names>JP</given-names></name><name><surname>Markowitz</surname> <given-names>S</given-names></name><name><surname>Willson</surname> <given-names>JK</given-names></name><name><surname>Hamilton</surname> <given-names>SR</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Kane</surname> <given-names>MF</given-names></name><name><surname>Kolodner</surname> <given-names>RD</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Kunkel</surname> <given-names>TA</given-names></name><name><surname>Baylin</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma</article-title><source>PNAS</source><volume>95</volume><fpage>6870</fpage><lpage>6875</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.12.6870</pub-id><pub-id pub-id-type="pmid">9618505</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickson</surname> <given-names>ID</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>RecQ helicases: caretakers of the genome</article-title><source>Nature Reviews Cancer</source><volume>3</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1038/nrc1012</pub-id><pub-id pub-id-type="pmid">12612652</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Gray</surname> <given-names>MD</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name><name><surname>Mian</surname> <given-names>IS</given-names></name><name><surname>Campisi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The premature ageing syndrome protein, WRN, is a 3'--&gt;5' exonuclease</article-title><source>Nature Genetics</source><volume>20</volume><fpage>114</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/2410</pub-id><pub-id pub-id-type="pmid">9771700</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>L</given-names></name><name><surname>Hanson</surname> <given-names>NB</given-names></name><name><surname>Lenaerts</surname> <given-names>C</given-names></name><name><surname>Hoehn</surname> <given-names>H</given-names></name><name><surname>Poot</surname> <given-names>M</given-names></name><name><surname>Rubin</surname> <given-names>CD</given-names></name><name><surname>Chen</surname> <given-names>DF</given-names></name><name><surname>Yang</surname> <given-names>CC</given-names></name><name><surname>Juch</surname> <given-names>H</given-names></name><name><surname>Dorn</surname> <given-names>T</given-names></name><name><surname>Spiegel</surname> <given-names>R</given-names></name><name><surname>Oral</surname> <given-names>EA</given-names></name><name><surname>Abid</surname> <given-names>M</given-names></name><name><surname>Battisti</surname> <given-names>C</given-names></name><name><surname>Lucci-Cordisco</surname> <given-names>E</given-names></name><name><surname>Neri</surname> <given-names>G</given-names></name><name><surname>Steed</surname> <given-names>EH</given-names></name><name><surname>Kidd</surname> <given-names>A</given-names></name><name><surname>Isley</surname> <given-names>W</given-names></name><name><surname>Showalter</surname> <given-names>D</given-names></name><name><surname>Vittone</surname> <given-names>JL</given-names></name><name><surname>Konstantinow</surname> <given-names>A</given-names></name><name><surname>Ring</surname> <given-names>J</given-names></name><name><surname>Meyer</surname> <given-names>P</given-names></name><name><surname>Wenger</surname> <given-names>SL</given-names></name><name><surname>von Herbay</surname> <given-names>A</given-names></name><name><surname>Wollina</surname> <given-names>U</given-names></name><name><surname>Schuelke</surname> <given-names>M</given-names></name><name><surname>Huizenga</surname> <given-names>CR</given-names></name><name><surname>Leistritz</surname> <given-names>DF</given-names></name><name><surname>Martin</surname> <given-names>GM</given-names></name><name><surname>Mian</surname> <given-names>IS</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The spectrum of WRN mutations in Werner syndrome patients</article-title><source>Human Mutation</source><volume>27</volume><fpage>558</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1002/humu.20337</pub-id><pub-id pub-id-type="pmid">16673358</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiricny</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The multifaceted mismatch-repair system</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>7</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nrm1907</pub-id><pub-id pub-id-type="pmid">16612326</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath-Loeb</surname> <given-names>AS</given-names></name><name><surname>Shen</surname> <given-names>JC</given-names></name><name><surname>Loeb</surname> <given-names>LA</given-names></name><name><surname>Fry</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Werner syndrome protein. II. characterization of the integral 3' --&gt; 5' DNA exonuclease</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>34145</fpage><lpage>34150</lpage><pub-id pub-id-type="pmid">9852074</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname> <given-names>MF</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Gaida</surname> <given-names>GM</given-names></name><name><surname>Lipman</surname> <given-names>J</given-names></name><name><surname>Mishra</surname> <given-names>R</given-names></name><name><surname>Goldman</surname> <given-names>H</given-names></name><name><surname>Jessup</surname> <given-names>JM</given-names></name><name><surname>Kolodner</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines</article-title><source>Cancer Research</source><volume>57</volume><fpage>808</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">9041175</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname> <given-names>B</given-names></name><name><surname>Shapira-Frommer</surname> <given-names>R</given-names></name><name><surname>Schmutzler</surname> <given-names>RK</given-names></name><name><surname>Audeh</surname> <given-names>MW</given-names></name><name><surname>Friedlander</surname> <given-names>M</given-names></name><name><surname>Balmaña</surname> <given-names>J</given-names></name><name><surname>Mitchell</surname> <given-names>G</given-names></name><name><surname>Fried</surname> <given-names>G</given-names></name><name><surname>Stemmer</surname> <given-names>SM</given-names></name><name><surname>Hubert</surname> <given-names>A</given-names></name><name><surname>Rosengarten</surname> <given-names>O</given-names></name><name><surname>Steiner</surname> <given-names>M</given-names></name><name><surname>Loman</surname> <given-names>N</given-names></name><name><surname>Bowen</surname> <given-names>K</given-names></name><name><surname>Fielding</surname> <given-names>A</given-names></name><name><surname>Domchek</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.2728</pub-id><pub-id pub-id-type="pmid">25366685</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cancer-susceptibility genes. Gatekeepers and caretakers</article-title><source>Nature</source><volume>386</volume><fpage>761</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/386761a0</pub-id><pub-id pub-id-type="pmid">9126728</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knijnenburg</surname> <given-names>TA</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Zimmermann</surname> <given-names>MT</given-names></name><name><surname>Chambwe</surname> <given-names>N</given-names></name><name><surname>Gao</surname> <given-names>GF</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Fan</surname> <given-names>H</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Way</surname> <given-names>GP</given-names></name><name><surname>Greene</surname> <given-names>CS</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Feng</surname> <given-names>B</given-names></name><name><surname>Donehower</surname> <given-names>LA</given-names></name><name><surname>Miller</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Karimi</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>P</given-names></name><name><surname>Jia</surname> <given-names>P</given-names></name><name><surname>Shinbrot</surname> <given-names>E</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Bailey</surname> <given-names>MH</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Wolf</surname> <given-names>D</given-names></name><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Shmulevich</surname> <given-names>I</given-names></name><name><surname>Monnat</surname> <given-names>RJ</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas</article-title><source>Cell Reports</source><volume>23</volume><fpage>239</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.076</pub-id><pub-id pub-id-type="pmid">29617664</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koi</surname> <given-names>M</given-names></name><name><surname>Umar</surname> <given-names>A</given-names></name><name><surname>Chauhan</surname> <given-names>DP</given-names></name><name><surname>Cherian</surname> <given-names>SP</given-names></name><name><surname>Carethers</surname> <given-names>JM</given-names></name><name><surname>Kunkel</surname> <given-names>TA</given-names></name><name><surname>Boland</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation</article-title><source>Cancer Research</source><volume>54</volume><fpage>4308</fpage><lpage>4312</lpage><pub-id pub-id-type="pmid">8044777</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korch</surname> <given-names>C</given-names></name><name><surname>Spillman</surname> <given-names>MA</given-names></name><name><surname>Jackson</surname> <given-names>TA</given-names></name><name><surname>Jacobsen</surname> <given-names>BM</given-names></name><name><surname>Murphy</surname> <given-names>SK</given-names></name><name><surname>Lessey</surname> <given-names>BA</given-names></name><name><surname>Jordan</surname> <given-names>VC</given-names></name><name><surname>Bradford</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination</article-title><source>Gynecologic Oncology</source><volume>127</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.06.017</pub-id><pub-id pub-id-type="pmid">22710073</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuismanen</surname> <given-names>SA</given-names></name><name><surname>Holmberg</surname> <given-names>MT</given-names></name><name><surname>Salovaara</surname> <given-names>R</given-names></name><name><surname>de la Chapelle</surname> <given-names>A</given-names></name><name><surname>Peltomäki</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers</article-title><source>The American Journal of Pathology</source><volume>156</volume><fpage>1773</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65048-1</pub-id><pub-id pub-id-type="pmid">10793088</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkel</surname> <given-names>TA</given-names></name><name><surname>Erie</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Eukaryotic mismatch repair in relation to DNA replication</article-title><source>Annual Review of Genetics</source><volume>49</volume><fpage>291</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-112414-054722</pub-id><pub-id pub-id-type="pmid">26436461</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauper</surname> <given-names>JM</given-names></name><name><surname>Krause</surname> <given-names>A</given-names></name><name><surname>Vaughan</surname> <given-names>TL</given-names></name><name><surname>Monnat</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Spectrum and risk of neoplasia in Werner syndrome: a systematic review</article-title><source>PLoS One</source><volume>8</volume><elocation-id>e59709</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0059709</pub-id><pub-id pub-id-type="pmid">23573208</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname> <given-names>DT</given-names></name><name><surname>Uram</surname> <given-names>JN</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Bartlett</surname> <given-names>BR</given-names></name><name><surname>Kemberling</surname> <given-names>H</given-names></name><name><surname>Eyring</surname> <given-names>AD</given-names></name><name><surname>Skora</surname> <given-names>AD</given-names></name><name><surname>Luber</surname> <given-names>BS</given-names></name><name><surname>Azad</surname> <given-names>NS</given-names></name><name><surname>Laheru</surname> <given-names>D</given-names></name><name><surname>Biedrzycki</surname> <given-names>B</given-names></name><name><surname>Donehower</surname> <given-names>RC</given-names></name><name><surname>Zaheer</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>GA</given-names></name><name><surname>Crocenzi</surname> <given-names>TS</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name><name><surname>Duffy</surname> <given-names>SM</given-names></name><name><surname>Goldberg</surname> <given-names>RM</given-names></name><name><surname>de la Chapelle</surname> <given-names>A</given-names></name><name><surname>Koshiji</surname> <given-names>M</given-names></name><name><surname>Bhaijee</surname> <given-names>F</given-names></name><name><surname>Huebner</surname> <given-names>T</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Cuka</surname> <given-names>N</given-names></name><name><surname>Pardoll</surname> <given-names>DM</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Cornish</surname> <given-names>TC</given-names></name><name><surname>Taube</surname> <given-names>JM</given-names></name><name><surname>Anders</surname> <given-names>RA</given-names></name><name><surname>Eshleman</surname> <given-names>JR</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title><source>New England Journal of Medicine</source><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmid">26028255</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname> <given-names>DT</given-names></name><name><surname>Durham</surname> <given-names>JN</given-names></name><name><surname>Smith</surname> <given-names>KN</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Bartlett</surname> <given-names>BR</given-names></name><name><surname>Aulakh</surname> <given-names>LK</given-names></name><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Kemberling</surname> <given-names>H</given-names></name><name><surname>Wilt</surname> <given-names>C</given-names></name><name><surname>Luber</surname> <given-names>BS</given-names></name><name><surname>Wong</surname> <given-names>F</given-names></name><name><surname>Azad</surname> <given-names>NS</given-names></name><name><surname>Rucki</surname> <given-names>AA</given-names></name><name><surname>Laheru</surname> <given-names>D</given-names></name><name><surname>Donehower</surname> <given-names>R</given-names></name><name><surname>Zaheer</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>GA</given-names></name><name><surname>Crocenzi</surname> <given-names>TS</given-names></name><name><surname>Lee</surname> <given-names>JJ</given-names></name><name><surname>Greten</surname> <given-names>TF</given-names></name><name><surname>Duffy</surname> <given-names>AG</given-names></name><name><surname>Ciombor</surname> <given-names>KK</given-names></name><name><surname>Eyring</surname> <given-names>AD</given-names></name><name><surname>Lam</surname> <given-names>BH</given-names></name><name><surname>Joe</surname> <given-names>A</given-names></name><name><surname>Kang</surname> <given-names>SP</given-names></name><name><surname>Holdhoff</surname> <given-names>M</given-names></name><name><surname>Danilova</surname> <given-names>L</given-names></name><name><surname>Cope</surname> <given-names>L</given-names></name><name><surname>Meyer</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Goldberg</surname> <given-names>RM</given-names></name><name><surname>Armstrong</surname> <given-names>DK</given-names></name><name><surname>Bever</surname> <given-names>KM</given-names></name><name><surname>Fader</surname> <given-names>AN</given-names></name><name><surname>Taube</surname> <given-names>J</given-names></name><name><surname>Housseau</surname> <given-names>F</given-names></name><name><surname>Spetzler</surname> <given-names>D</given-names></name><name><surname>Xiao</surname> <given-names>N</given-names></name><name><surname>Pardoll</surname> <given-names>DM</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Eshleman</surname> <given-names>JR</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Anders</surname> <given-names>RA</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title><source>Science</source><volume>357</volume><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id><pub-id pub-id-type="pmid">28596308</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebel</surname> <given-names>M</given-names></name><name><surname>Leder</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A deletion within the murine werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity</article-title><source>PNAS</source><volume>95</volume><fpage>13097</fpage><lpage>13102</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.22.13097</pub-id><pub-id pub-id-type="pmid">9789047</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombard</surname> <given-names>DB</given-names></name><name><surname>Beard</surname> <given-names>C</given-names></name><name><surname>Johnson</surname> <given-names>B</given-names></name><name><surname>Marciniak</surname> <given-names>RA</given-names></name><name><surname>Dausman</surname> <given-names>J</given-names></name><name><surname>Bronson</surname> <given-names>R</given-names></name><name><surname>Buhlmann</surname> <given-names>JE</given-names></name><name><surname>Lipman</surname> <given-names>R</given-names></name><name><surname>Curry</surname> <given-names>R</given-names></name><name><surname>Sharpe</surname> <given-names>A</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name><name><surname>Guarente</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Mutations in the WRN gene in mice accelerate mortality in a p53-null background</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>3286</fpage><lpage>3291</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.9.3286-3291.2000</pub-id><pub-id pub-id-type="pmid">10757812</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARP inhibitors: Synthetic lethality in the clinic</article-title><source>Science</source><volume>355</volume><fpage>1152</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1126/science.aam7344</pub-id><pub-id pub-id-type="pmid">28302823</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname> <given-names>HT</given-names></name><name><surname>Snyder</surname> <given-names>CL</given-names></name><name><surname>Shaw</surname> <given-names>TG</given-names></name><name><surname>Heinen</surname> <given-names>CD</given-names></name><name><surname>Hitchins</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Milestones of Lynch syndrome: 1895-2015</article-title><source>Nature Reviews Cancer</source><volume>15</volume><fpage>181</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nrc3878</pub-id><pub-id pub-id-type="pmid">25673086</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname> <given-names>HT</given-names></name><name><surname>Krush</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Cancer family &quot;G&quot; revisited: 1895-1970</article-title><source>Cancer</source><volume>27</volume><fpage>1505</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197106)27:6&lt;1505::AID-CNCR2820270635&gt;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">5088221</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname> <given-names>KJ</given-names></name><name><surname>Carroll</surname> <given-names>P</given-names></name><name><surname>Martin</surname> <given-names>CA</given-names></name><name><surname>Murina</surname> <given-names>O</given-names></name><name><surname>Fluteau</surname> <given-names>A</given-names></name><name><surname>Simpson</surname> <given-names>DJ</given-names></name><name><surname>Olova</surname> <given-names>N</given-names></name><name><surname>Sutcliffe</surname> <given-names>H</given-names></name><name><surname>Rainger</surname> <given-names>JK</given-names></name><name><surname>Leitch</surname> <given-names>A</given-names></name><name><surname>Osborn</surname> <given-names>RT</given-names></name><name><surname>Wheeler</surname> <given-names>AP</given-names></name><name><surname>Nowotny</surname> <given-names>M</given-names></name><name><surname>Gilbert</surname> <given-names>N</given-names></name><name><surname>Chandra</surname> <given-names>T</given-names></name><name><surname>Reijns</surname> <given-names>MAM</given-names></name><name><surname>Jackson</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cGAS surveillance of micronuclei links genome instability to innate immunity</article-title><source>Nature</source><volume>548</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nature23449</pub-id><pub-id pub-id-type="pmid">28738408</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname> <given-names>T</given-names></name><name><surname>Shimamoto</surname> <given-names>A</given-names></name><name><surname>Goto</surname> <given-names>M</given-names></name><name><surname>Furuichi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Impaired nuclear localization of defective DNA helicases in Werner's syndrome</article-title><source>Nature Genetics</source><volume>16</volume><fpage>335</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/ng0897-335</pub-id><pub-id pub-id-type="pmid">9241267</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname> <given-names>ER</given-names></name><name><surname>de Weck</surname> <given-names>A</given-names></name><name><surname>Schlabach</surname> <given-names>MR</given-names></name><name><surname>Billy</surname> <given-names>E</given-names></name><name><surname>Mavrakis</surname> <given-names>KJ</given-names></name><name><surname>Hoffman</surname> <given-names>GR</given-names></name><name><surname>Belur</surname> <given-names>D</given-names></name><name><surname>Castelletti</surname> <given-names>D</given-names></name><name><surname>Frias</surname> <given-names>E</given-names></name><name><surname>Gampa</surname> <given-names>K</given-names></name><name><surname>Golji</surname> <given-names>J</given-names></name><name><surname>Kao</surname> <given-names>I</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Megel</surname> <given-names>P</given-names></name><name><surname>Perkins</surname> <given-names>TA</given-names></name><name><surname>Ramadan</surname> <given-names>N</given-names></name><name><surname>Ruddy</surname> <given-names>DA</given-names></name><name><surname>Silver</surname> <given-names>SJ</given-names></name><name><surname>Sovath</surname> <given-names>S</given-names></name><name><surname>Stump</surname> <given-names>M</given-names></name><name><surname>Weber</surname> <given-names>O</given-names></name><name><surname>Widmer</surname> <given-names>R</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Yue</surname> <given-names>Y</given-names></name><name><surname>Abramowski</surname> <given-names>D</given-names></name><name><surname>Ackley</surname> <given-names>E</given-names></name><name><surname>Barrett</surname> <given-names>R</given-names></name><name><surname>Berger</surname> <given-names>J</given-names></name><name><surname>Bernard</surname> <given-names>JL</given-names></name><name><surname>Billig</surname> <given-names>R</given-names></name><name><surname>Brachmann</surname> <given-names>SM</given-names></name><name><surname>Buxton</surname> <given-names>F</given-names></name><name><surname>Caothien</surname> <given-names>R</given-names></name><name><surname>Caushi</surname> <given-names>JX</given-names></name><name><surname>Chung</surname> <given-names>FS</given-names></name><name><surname>Cortés-Cros</surname> <given-names>M</given-names></name><name><surname>deBeaumont</surname> <given-names>RS</given-names></name><name><surname>Delaunay</surname> <given-names>C</given-names></name><name><surname>Desplat</surname> <given-names>A</given-names></name><name><surname>Duong</surname> <given-names>W</given-names></name><name><surname>Dwoske</surname> <given-names>DA</given-names></name><name><surname>Eldridge</surname> <given-names>RS</given-names></name><name><surname>Farsidjani</surname> <given-names>A</given-names></name><name><surname>Feng</surname> <given-names>F</given-names></name><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Flemming</surname> <given-names>D</given-names></name><name><surname>Forrester</surname> <given-names>W</given-names></name><name><surname>Galli</surname> <given-names>GG</given-names></name><name><surname>Gao</surname> <given-names>Z</given-names></name><name><surname>Gauter</surname> <given-names>F</given-names></name><name><surname>Gibaja</surname> <given-names>V</given-names></name><name><surname>Haas</surname> <given-names>K</given-names></name><name><surname>Hattenberger</surname> <given-names>M</given-names></name><name><surname>Hood</surname> <given-names>T</given-names></name><name><surname>Hurov</surname> <given-names>KE</given-names></name><name><surname>Jagani</surname> <given-names>Z</given-names></name><name><surname>Jenal</surname> <given-names>M</given-names></name><name><surname>Johnson</surname> <given-names>JA</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Kapoor</surname> <given-names>A</given-names></name><name><surname>Korn</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Loo</surname> <given-names>AT</given-names></name><name><surname>Macchi</surname> <given-names>KJ</given-names></name><name><surname>Martin</surname> <given-names>T</given-names></name><name><surname>McAllister</surname> <given-names>G</given-names></name><name><surname>Meyer</surname> <given-names>A</given-names></name><name><surname>Mollé</surname> <given-names>S</given-names></name><name><surname>Pagliarini</surname> <given-names>RA</given-names></name><name><surname>Phadke</surname> <given-names>T</given-names></name><name><surname>Repko</surname> <given-names>B</given-names></name><name><surname>Schouwey</surname> <given-names>T</given-names></name><name><surname>Shanahan</surname> <given-names>F</given-names></name><name><surname>Shen</surname> <given-names>Q</given-names></name><name><surname>Stamm</surname> <given-names>C</given-names></name><name><surname>Stephan</surname> <given-names>C</given-names></name><name><surname>Stucke</surname> <given-names>VM</given-names></name><name><surname>Tiedt</surname> <given-names>R</given-names></name><name><surname>Varadarajan</surname> <given-names>M</given-names></name><name><surname>Venkatesan</surname> <given-names>K</given-names></name><name><surname>Vitari</surname> <given-names>AC</given-names></name><name><surname>Wallroth</surname> <given-names>M</given-names></name><name><surname>Weiler</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Mickanin</surname> <given-names>C</given-names></name><name><surname>Myer</surname> <given-names>VE</given-names></name><name><surname>Porter</surname> <given-names>JA</given-names></name><name><surname>Lai</surname> <given-names>A</given-names></name><name><surname>Bitter</surname> <given-names>H</given-names></name><name><surname>Lees</surname> <given-names>E</given-names></name><name><surname>Keen</surname> <given-names>N</given-names></name><name><surname>Kauffmann</surname> <given-names>A</given-names></name><name><surname>Stegmeier</surname> <given-names>F</given-names></name><name><surname>Hofmann</surname> <given-names>F</given-names></name><name><surname>Schmelzle</surname> <given-names>T</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by Large-Scale, deep RNAi screening</article-title><source>Cell</source><volume>170</volume><fpage>577</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.07.005</pub-id><pub-id pub-id-type="pmid">28753431</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medico</surname> <given-names>E</given-names></name><name><surname>Russo</surname> <given-names>M</given-names></name><name><surname>Picco</surname> <given-names>G</given-names></name><name><surname>Cancelliere</surname> <given-names>C</given-names></name><name><surname>Valtorta</surname> <given-names>E</given-names></name><name><surname>Corti</surname> <given-names>G</given-names></name><name><surname>Buscarino</surname> <given-names>M</given-names></name><name><surname>Isella</surname> <given-names>C</given-names></name><name><surname>Lamba</surname> <given-names>S</given-names></name><name><surname>Martinoglio</surname> <given-names>B</given-names></name><name><surname>Veronese</surname> <given-names>S</given-names></name><name><surname>Siena</surname> <given-names>S</given-names></name><name><surname>Sartore-Bianchi</surname> <given-names>A</given-names></name><name><surname>Beccuti</surname> <given-names>M</given-names></name><name><surname>Mottolese</surname> <given-names>M</given-names></name><name><surname>Linnebacher</surname> <given-names>M</given-names></name><name><surname>Cordero</surname> <given-names>F</given-names></name><name><surname>Di Nicolantonio</surname> <given-names>F</given-names></name><name><surname>Bardelli</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7002</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8002</pub-id><pub-id pub-id-type="pmid">25926053</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickoloff</surname> <given-names>JA</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>S-H</given-names></name><name><surname>Williamson</surname> <given-names>EA</given-names></name><name><surname>Hromas</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Drugging the cancers addicted to DNA repair</article-title><source>JNCI: Journal of the National Cancer Institute</source><volume>109</volume><pub-id pub-id-type="doi">10.1093/jnci/djx059</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname> <given-names>V</given-names></name><name><surname>Brown</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Signalling cell cycle arrest and cell death through the MMR System</article-title><source>Carcinogenesis</source><volume>27</volume><fpage>682</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi298</pub-id><pub-id pub-id-type="pmid">16332722</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oike</surname> <given-names>T</given-names></name><name><surname>Ogiwara</surname> <given-names>H</given-names></name><name><surname>Tominaga</surname> <given-names>Y</given-names></name><name><surname>Ito</surname> <given-names>K</given-names></name><name><surname>Ando</surname> <given-names>O</given-names></name><name><surname>Tsuta</surname> <given-names>K</given-names></name><name><surname>Mizukami</surname> <given-names>T</given-names></name><name><surname>Shimada</surname> <given-names>Y</given-names></name><name><surname>Isomura</surname> <given-names>H</given-names></name><name><surname>Komachi</surname> <given-names>M</given-names></name><name><surname>Furuta</surname> <given-names>K</given-names></name><name><surname>Watanabe</surname> <given-names>S</given-names></name><name><surname>Nakano</surname> <given-names>T</given-names></name><name><surname>Yokota</surname> <given-names>J</given-names></name><name><surname>Kohno</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1</article-title><source>Cancer Research</source><volume>73</volume><fpage>5508</fpage><lpage>5518</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-4593</pub-id><pub-id pub-id-type="pmid">23872584</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshima</surname> <given-names>J</given-names></name><name><surname>Sidorova</surname> <given-names>JM</given-names></name><name><surname>Monnat</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions</article-title><source>Ageing Research Reviews</source><volume>33</volume><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2016.03.002</pub-id><pub-id pub-id-type="pmid">26993153</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overman</surname> <given-names>MJ</given-names></name><name><surname>Lonardi</surname> <given-names>S</given-names></name><name><surname>Wong</surname> <given-names>KYM</given-names></name><name><surname>Lenz</surname> <given-names>HJ</given-names></name><name><surname>Gelsomino</surname> <given-names>F</given-names></name><name><surname>Aglietta</surname> <given-names>M</given-names></name><name><surname>Morse</surname> <given-names>MA</given-names></name><name><surname>Van Cutsem</surname> <given-names>E</given-names></name><name><surname>McDermott</surname> <given-names>R</given-names></name><name><surname>Hill</surname> <given-names>A</given-names></name><name><surname>Sawyer</surname> <given-names>MB</given-names></name><name><surname>Hendlisz</surname> <given-names>A</given-names></name><name><surname>Neyns</surname> <given-names>B</given-names></name><name><surname>Svrcek</surname> <given-names>M</given-names></name><name><surname>Moss</surname> <given-names>RA</given-names></name><name><surname>Ledeine</surname> <given-names>JM</given-names></name><name><surname>Cao</surname> <given-names>ZA</given-names></name><name><surname>Kamble</surname> <given-names>S</given-names></name><name><surname>Kopetz</surname> <given-names>S</given-names></name><name><surname>André</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer</article-title><source>Journal of Clinical Oncology</source><volume>36</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.76.9901</pub-id><pub-id pub-id-type="pmid">29355075</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prince</surname> <given-names>PR</given-names></name><name><surname>Emond</surname> <given-names>MJ</given-names></name><name><surname>Monnat</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Loss of Werner syndrome protein function promotes aberrant mitotic recombination</article-title><source>Genes &amp; Development</source><volume>15</volume><fpage>933</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1101/gad.877001</pub-id><pub-id pub-id-type="pmid">11316787</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Qi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><chapter-title>Random Forest for Bioinformatics</chapter-title><person-group person-group-type="editor"><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name></person-group><source>Ensemble Machine Learning: Methods and Applications</source><publisher-loc>Boston</publisher-loc><publisher-name>Springer</publisher-name><fpage>307</fpage><lpage>323</lpage></element-citation></ref><ref id="bib53"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rosenthal</surname> <given-names>AS</given-names></name><name><surname>Dexheimer</surname> <given-names>TS</given-names></name><name><surname>Nguyen</surname> <given-names>G</given-names></name><name><surname>Gileadi</surname> <given-names>O</given-names></name><name><surname>Vindigni</surname> <given-names>A</given-names></name><name><surname>Simeonov</surname> <given-names>A</given-names></name><name><surname>Maloney</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><chapter-title>Discovery of ML216, a small molecule inhibitor of bloom (BLM) Helicase</chapter-title><source>Probe Reports from the NIH Molecular Libraries Program</source><publisher-loc>Bethesda, United States</publisher-loc><publisher-name>National Center for Biotechnology Information</publisher-name></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>JC</given-names></name><name><surname>Gray</surname> <given-names>MD</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name><name><surname>Kamath-Loeb</surname> <given-names>AS</given-names></name><name><surname>Fry</surname> <given-names>M</given-names></name><name><surname>Loeb</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Werner syndrome protein. I. DNA helicase and dna exonuclease reside on the same polypeptide</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>34139</fpage><lpage>34144</lpage><pub-id pub-id-type="pmid">9852073</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Milazzo</surname> <given-names>JP</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Kinney</surname> <given-names>JB</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>661</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1038/nbt.3235</pub-id><pub-id pub-id-type="pmid">25961408</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname> <given-names>M</given-names></name><name><surname>Gratzl</surname> <given-names>S</given-names></name><name><surname>Stitz</surname> <given-names>H</given-names></name><name><surname>Wernitznig</surname> <given-names>A</given-names></name><name><surname>Zichner</surname> <given-names>T</given-names></name><name><surname>Haslinger</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ordino: a visual cancer analysis tool for ranking and exploring genes, cell lines, and tissue samples</article-title><source>Bioinformatics</source><pub-id pub-id-type="doi">10.1093/bioinformatics/btz009</pub-id><pub-id pub-id-type="pmid">30657871</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umar</surname> <given-names>A</given-names></name><name><surname>Boland</surname> <given-names>CR</given-names></name><name><surname>Terdiman</surname> <given-names>JP</given-names></name><name><surname>Syngal</surname> <given-names>S</given-names></name><name><surname>de la Chapelle</surname> <given-names>A</given-names></name><name><surname>Rüschoff</surname> <given-names>J</given-names></name><name><surname>Fishel</surname> <given-names>R</given-names></name><name><surname>Lindor</surname> <given-names>NM</given-names></name><name><surname>Burgart</surname> <given-names>LJ</given-names></name><name><surname>Hamelin</surname> <given-names>R</given-names></name><name><surname>Hamilton</surname> <given-names>SR</given-names></name><name><surname>Hiatt</surname> <given-names>RA</given-names></name><name><surname>Jass</surname> <given-names>J</given-names></name><name><surname>Lindblom</surname> <given-names>A</given-names></name><name><surname>Lynch</surname> <given-names>HT</given-names></name><name><surname>Peltomaki</surname> <given-names>P</given-names></name><name><surname>Ramsey</surname> <given-names>SD</given-names></name><name><surname>Rodriguez-Bigas</surname> <given-names>MA</given-names></name><name><surname>Vasen</surname> <given-names>HF</given-names></name><name><surname>Hawk</surname> <given-names>ET</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name><name><surname>Freedman</surname> <given-names>AN</given-names></name><name><surname>Srivastava</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability</article-title><source>JNCI Journal of the National Cancer Institute</source><volume>96</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/jnci/djh034</pub-id><pub-id pub-id-type="pmid">14970275</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Lelij</surname> <given-names>P</given-names></name><name><surname>Lieb</surname> <given-names>S</given-names></name><name><surname>Jude</surname> <given-names>J</given-names></name><name><surname>Wutz</surname> <given-names>G</given-names></name><name><surname>Santos</surname> <given-names>CP</given-names></name><name><surname>Falkenberg</surname> <given-names>K</given-names></name><name><surname>Schlattl</surname> <given-names>A</given-names></name><name><surname>Ban</surname> <given-names>J</given-names></name><name><surname>Schwentner</surname> <given-names>R</given-names></name><name><surname>Hoffmann</surname> <given-names>T</given-names></name><name><surname>Kovar</surname> <given-names>H</given-names></name><name><surname>Real</surname> <given-names>FX</given-names></name><name><surname>Waldman</surname> <given-names>T</given-names></name><name><surname>Pearson</surname> <given-names>MA</given-names></name><name><surname>Kraut</surname> <given-names>N</given-names></name><name><surname>Peters</surname> <given-names>JM</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Petronczki</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Synthetic lethality between the cohesin subunits <italic>STAG1</italic> and <italic>STAG2</italic> in diverse cancer contexts</article-title><source>eLife</source><volume>6</volume><elocation-id>e26980</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26980</pub-id><pub-id pub-id-type="pmid">28691904</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokote</surname> <given-names>K</given-names></name><name><surname>Chanprasert</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>L</given-names></name><name><surname>Eirich</surname> <given-names>K</given-names></name><name><surname>Takemoto</surname> <given-names>M</given-names></name><name><surname>Watanabe</surname> <given-names>A</given-names></name><name><surname>Koizumi</surname> <given-names>N</given-names></name><name><surname>Lessel</surname> <given-names>D</given-names></name><name><surname>Mori</surname> <given-names>T</given-names></name><name><surname>Hisama</surname> <given-names>FM</given-names></name><name><surname>Ladd</surname> <given-names>PD</given-names></name><name><surname>Angle</surname> <given-names>B</given-names></name><name><surname>Baris</surname> <given-names>H</given-names></name><name><surname>Cefle</surname> <given-names>K</given-names></name><name><surname>Palanduz</surname> <given-names>S</given-names></name><name><surname>Ozturk</surname> <given-names>S</given-names></name><name><surname>Chateau</surname> <given-names>A</given-names></name><name><surname>Deguchi</surname> <given-names>K</given-names></name><name><surname>Easwar</surname> <given-names>TK</given-names></name><name><surname>Federico</surname> <given-names>A</given-names></name><name><surname>Fox</surname> <given-names>A</given-names></name><name><surname>Grebe</surname> <given-names>TA</given-names></name><name><surname>Hay</surname> <given-names>B</given-names></name><name><surname>Nampoothiri</surname> <given-names>S</given-names></name><name><surname>Seiter</surname> <given-names>K</given-names></name><name><surname>Streeten</surname> <given-names>E</given-names></name><name><surname>Piña-Aguilar</surname> <given-names>RE</given-names></name><name><surname>Poke</surname> <given-names>G</given-names></name><name><surname>Poot</surname> <given-names>M</given-names></name><name><surname>Posmyk</surname> <given-names>R</given-names></name><name><surname>Martin</surname> <given-names>GM</given-names></name><name><surname>Kubisch</surname> <given-names>C</given-names></name><name><surname>Schindler</surname> <given-names>D</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>WRN mutation update: mutation spectrum, patient registries, and translational prospects</article-title><source>Human Mutation</source><volume>38</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1002/humu.23128</pub-id><pub-id pub-id-type="pmid">27667302</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>CE</given-names></name><name><surname>Oshima</surname> <given-names>J</given-names></name><name><surname>Fu</surname> <given-names>YH</given-names></name><name><surname>Wijsman</surname> <given-names>EM</given-names></name><name><surname>Hisama</surname> <given-names>F</given-names></name><name><surname>Alisch</surname> <given-names>R</given-names></name><name><surname>Matthews</surname> <given-names>S</given-names></name><name><surname>Nakura</surname> <given-names>J</given-names></name><name><surname>Miki</surname> <given-names>T</given-names></name><name><surname>Ouais</surname> <given-names>S</given-names></name><name><surname>Martin</surname> <given-names>GM</given-names></name><name><surname>Mulligan</surname> <given-names>J</given-names></name><name><surname>Schellenberg</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Positional cloning of the Werner's syndrome gene</article-title><source>Science</source><volume>272</volume><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">8602509</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.43333.024</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, Davis</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Heyer</surname><given-names>Wolf-Dietrich</given-names> </name><role>Reviewer</role><aff><institution>University of California, Davis</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Monnat</surname><given-names>Ray</given-names> </name><role>Reviewer</role><aff><institution>University of Washington</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Cejka</surname><given-names>Petr</given-names> </name><role>Reviewer</role><aff><institution>Institute for Research in Biomedicine</institution><country>Switzerland</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Wolf-Dietrich Heyer as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jeffrey Settleman as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ray Monnat (Reviewer #2); Petr Cejka (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This intriguing new report identifies the WRN RecQ helicase as a new and potentially useful vulnerability in microsatellite-unstable ('MSI-high or MSI-H') cancer cell lines. The results are worth reporting after some additional work on the manuscript.</p><p>The authors identified a dependency of MMR-deficient cells on the RecQ-like helicase WRN, which constitutes a significant novel finding with far-reaching implications for improving treatment of MMR-deficient tumors. The selective dependency was identified in a large screen of 398 cancer cell models covering ~8,000 genes as published in 2017 and the correlation of MMR status and WRN dependency is highly significant (Figure 1). The observation is validated in multiple cell line models for MMR+ and MMR- colorectal cancer and endometrial cancer cell lines (Figure 2) and with WRN KO in 2 independent MMR+ and MMR- colorectal cancer cell lines (Figure 3) using viability and colony forming assays. Back-complementation activity depended on the WRN ATPase/helicase activity but not the nuclease activity in HCT 116 cells (Figure 4). The results with another MMR- cell line, RKO, are less clear (Figure 4—figure supplement 1, see below), suggesting the involvement of additional variables. Figure 5, Figure 6 and Figure 7 demonstrate that WRN knockdown in MMR-deficient cells leads to hallmarks of genomic instability including bridges and micronuclei (Figure 5), which is confirmed by life imaging (Figure 6) and endpoint analysis of mitotic spreads (Figure 7). The claims of the manuscript are largely well supported by the data with one exception (see essential points). Overall, the authors consistently use multiple cell lines and approaches to corroborate the dependence of MMR-deficient cells on WRN. The manuscript is very well written, and the results are displayed very clearly in the Figures and Tables.</p><p>Essential revisions:</p><p>1) Figure 4—figure supplement 1 and subsection “WRN dependency in MSI-H CRC is linked to its helicase function”: There is a significant difference between the back-complementation results in HCT 116 (Figure 4) and RKO (Figure 4—figure supplement 1) and the description in the text does not reflect the results of Figure 4—figure supplement 1. Figure 4 shows that the back-complementation with wildtype and nuclease-deficient WRN is very effective, whereas the ATPase/helicase-deficient mutant as well as the ATPase/helicase nuclease double mutant cannot complement the WRN siRNA knockdown cells. For RKO (Figure 4—figure supplement 1), the difference between nuclease and helicase mutants appears statistically insignificant as the error bars overlap. The text should be changed to more accurately reflect these results.</p><p>2) The authors meticulously show the dependence of the effect on WRN status, but the dependence on MMR status is only correlative. A key concern is that all experiments were carried upon depletion of WRN in MMR-deficient cell lines. These cell lines have a high mutator phenotype and accumulate mutations in a number of other genes, in particular in those containing microsatellites. Therefore, to confirm the key conclusion of this manuscript that the lethality is a result of simultaneous MMR and WRN deficiency, the experiment should also done the other way round, i.e. to deplete key MMR factors (MLH1 would be the best) in WRN-deficient cells, or to perform co-depletion experiments. Additionally, WRN depletion should also be carried out in HCT 116 +ch3 cell line, in which the expression of MLH1 was corrected.</p><p>HCT 116 and RKO are both MLH1 deficient. What is known about additional mutations in these cell lines that may contribute to this difference? This above approach might also address the difference between both cell lines. For RKO a complementation system was described in Yan et al., 2003.</p><p>3) WRN inhibitors need to be referenced and discussed more fully. In addition to the Rosenthal et al., 2010 reference, at least two WRN inhibitors have been around for 5+ years. They are highly and directly relevant to the topic of this manuscript, and are being pursued in other clinical contexts (see, e.g., Moles et al., 2016) that may provide additional insight. These inhibitors are readily available, and the authors' results make a straight-ahead prediction of what a dose-response outcome should be in their CRC cell line panels to provide a bit of pre-clinical data. The authors should acquire the WRN inhibitors and do dose-response curves on their MSI-H and MSS cell lines, and show that their WRN KO lines are insensitive (or largely insensitive) as a demonstration of target specificity.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells&quot; for further consideration at <italic>eLife</italic>. Your revised article has been favorably evaluated by Jeffrey Settleman (Senior Editor), a Reviewing Editor, and two reviewers.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>The Abstract should be updated to reflect the significant insight that the MHL1 WRN synthetic lethality is context-dependent and not absolute.</p><p><italic>Reviewer #1:</italic> </p><p>In this revision the authors meticulously addressed the comments made in the initial review. They conducted significant new experimentation that strengthens the conclusion about the role of the nuclease activity of WRN (essential revision 1).</p><p>The authors devoted significant efforts to address essential revision 2, conducting 3 lines of experimentation that clearly demonstrate that the MLH1 WRN synthetic lethality is not hard wired but is context dependent. This significantly affects the overall conclusion of the study, and it is very important that these new data were included in the revision and discussed. What I am missing is an update of the abstract to reflect this important point.</p><p>The authors also nicely addressed essential revision 3 testing 2 WRN inhibitors and 2 controls in their cell models. The results provide important insights about the inhibitors but do not contribute much mechanistic insight regarding the MLH1 WRN synthetic lethality. While the authors briefly refer to WRN inhibitors in the discussion, they elected not to include the data in the manuscript. I agree with their choice, as the inhibitors show little promise in terms of target specificity.</p><p>Point for final acceptance:</p><p>Update the Abstract to reflect the major conclusion that the MLH1 WRN synthetic lethality is context dependent and not absolute.</p><p><italic>Reviewer #3:</italic> </p><p>The authors carried out experiments to address issues raised during the initial revision.</p><p>I now support publication of this paper. Although the effect seems &quot;indirect&quot; as far as MMR status is concerned, it is still very significant with regards to the therapeutic potential. Also, this is now a very competitive topic.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.43333.025</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Figure 4—figure supplement 1 and subsection “WRN dependency in MSI-H CRC is linked to its helicase function”: There is a significant difference between the back-complementation results in HCT 116 (Figure 4) and RKO (Figure 4—figure supplement 1) and the description in the text does not reflect the results of Figure 4—figure supplement 1. Figure 4 shows that the back-complementation with wildtype and nuclease-deficient WRN is very effective, whereas the ATPase/helicase-deficient mutant as well as the ATPase/helicase nuclease double mutant cannot complement the WRN siRNA knockdown cells. For RKO (Figure 4—figure supplement 1), the difference between nuclease and helicase mutants appears statistically insignificant as the error bars overlap. The text should be changed to more accurately reflect these results.</p></disp-quote><p>We agree with the reviewer’s analysis that in RKO cells the back-complementation studies do not clearly indicate the differential relevance of helicase and nuclease function in the context of WRN dependence. We have revised the text in the manuscript accordingly:</p><p>“In RKO cells expressing WRNr variants, we observed a slightly a stronger dependency on WRN helicase ATP-binding function compared to exonuclease activity upon knock-down of endogenous WRN”.</p><p>Since the determination of the relevant enzymatic function of WRN in MSI-H cancer cells is critical for both the mechanistic understanding and from a drug development perspective we have performed WRN back-complementation experiments in an additional WRN-dependent MSI-H cell model, the endometrial carcinoma cell line HEC-265. We generated monoclonal lines with stable expression of FLAG-tagged, siRNA-resistant WRN (WRNr) expression constructs harboring loss-of-function mutations within the exonuclease- (E84A, Nuclease-dead) and helicase-domain (K577M, ATP-binding deficient), or both domains (E84A/K577M, Double-mutant). Similar to the findings in HCT 116 cell we observed that exogenous expression of the nuclease-dead form of WRNr, but not the ATP-binding deficient and double-mutant forms rescued the effect of endogenous WRN depletion. WRNr expression levels were similar or higher for the mutant WRNr variants compared to WRNr wild-type.</p><p>This data, which we have included in the revised version of the manuscript as Figure 4—figure supplement 1C, is supportive for a predominant function of WRN helicase in MSI cancer cell lines.</p><disp-quote content-type="editor-comment"><p>2) The authors meticulously show the dependence of the effect on WRN status, but the dependence on MMR status is only correlative. A key concern is that all experiments were carried upon depletion of WRN in MMR-deficient cell lines. These cell lines have a high mutator phenotype and accumulate mutations in a number of other genes, in particular in those containing microsatellites. Therefore, to confirm the key conclusion of this manuscript that the lethality is a result of simultaneous MMR and WRN deficiency, the experiment should also done the other way round, i.e. to deplete key MMR factors (MLH1 would be the best) in WRN-deficient cells, or to perform co-depletion experiments. Additionally, WRN depletion should also be carried out in HC T116 +ch3 cell line, in which the expression of MLH1 was corrected.</p><p>HCT 116 and RKO are both MLH1 deficient. What is known about additional mutations in these cell lines that may contribute to this difference? This above approach might also address the difference between both cell lines. For RKO a complementation system was described in Yan et al., 2003.</p></disp-quote><p>We agree that demonstrating whether WRN dependency of MSI-H cancer cell lines is attributable to an acute and context-independent synthetic lethal interaction or an acquired vulnerability related to the MMR-deficient status of these cell lines would substantially strengthen the relevance of this study. In line with the reviewers’ suggestions we have therefore addressed a potential co-dependence of WRN and MMR gene function with several approaches:</p><p>1) Test of differential WRN dependency in wild-type vs. MLH1-knock-out models of SW480 and CaCo-2.</p><p>2) Test of differential WRN dependency in parental vs. MLH1 and MLH1/MSH3 reconstituted HCT 116 cell lines (HCT 116 +ch3, HCT 116 +ch3/5).</p><p>3) Test of differential MLH1/MSH3 dependency in parental vs. WRN-knock-out models of SW480.</p><p>1) Test of differential WRN dependency in wild-type vs. MLH1-knock-out models of SW480 and CaCo-2.</p><p>To monitor whether loss of MLH1 would induce WRN dependency we generated MLH1-deficient clones in two MSS CRC cell lines (SW480 and CaCo-2) using CRISPR-Cas9 mediated gene knock-out and applied siRNA-mediated knock-down of WRN.</p><p>For both SW480- and CaCo-2-derived MLH1 knock-out clones we did not observe increased sensitivity to WRN knock-down compared to non-edited, wild-type clones. This indicates that at least in the context of established MSS CRC cancer cell lines MLH1 loss-of-function alone does not induce WRN dependency. Of note, WRN dependency was also not observed at later passages and MLH1 knock-out did not induce MSI in both models at &gt;9 months cultivation post MLH1 knock-out.</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.43333.021</object-id><label>Author response image 1.</label><caption><title>SW480 (upper panel) and CaCo-2 (lower panel) parental and MLH1-knock-out monoclonal CRC cell lines were transfected with the indicated siRNAs.</title><p>Cell viability was determined 7 days after transfection and is shown relative to non-targeting control (NTC) siRNA (n=3 biological replicates; error bars denote standard deviation). Knock-out of MLH1 was confirmed by immunoblotting.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-43333-resp-fig1-v1"/></fig><p>2) Test of differential WRN dependency in parental vs. MLH1 and MLH1/MSH3 reconstituted HCT 116 cell lines (HCT 116 +ch3, HCT 116 +ch3 +ch5)</p><p>We thank the reviewer for pointing out the HCT 116 +ch3 cell line as a semi-isogenic, MLH1-proficient model to the parental MMR-deficient HCT 116 cell line used in our study. We have analyzed the effect of WRN knock-down in the HCT 116 +ch3 cells along with the MMR-deficient control line HCT 116 +ch2 and the HCT 116 +ch3 +ch5 line (with additional complementation of MSH3). We find that neither back-complementation of MLH1 alone or in combination with MSH3 reverses the strong WRN dependency of HCT 116 cells – although we observe a slightly increased viability upon WRN knock-down in the HCT 116 +ch3 and HCT 116 +ch3 +ch5 models compared to HCT 116 parental cells and the +ch2 reconstituted control model (Figure 2—figure supplement 2A). siRNA-mediated depletion of WRN mRNA was equally efficient in all cell models (Figure 2—figure supplement 2B).</p><p>3) Test of differential MLH1/ MSH3 dependency in parental vs. WRN-knock-out models of SW480.</p><p>To monitor whether loss of WRN would induce dependency on MLH1 and/or MSH3, we analyzed the effect of individual or combined knock-down of MLH1 and MSH3 on the viability of wild-type (WRN-proficient) and two WRN-knock-out monoclonal SW480 cell lines. Neither single nor concomitant knock-down of MHL1 and MSH3 affected cell viability of the WRN-deficient SW480 cell lines (Figure 2—figure supplement 3A) despite efficacious knock-down of both genes (Figure 2—figure supplement 3B). This data is in line with the studies outlined above and argue against an acute and direct synthetic lethal interaction of WRN and MLH1/MSH3 genes.</p><p>In summary, the results outlined above suggest that the WRN dependence of MSI-H/MMR-deficient cancer cell lines might not be attributable to a hard-wired, context independent synthetic lethality such as described for the paralog genes STAG1/STAG2 (van der Lelij et al., 2017) or SMARCA2/SMARCA4 (Oike et al., 2013). Instead, our data argue for an acquired dependency on WRN function as a consequence of persistent MSI-H status and/or MMR-deficiency.</p><p>To incorporate this relevant finding we have included the studies using the MLH1/<italic>MLH3</italic> reconstituted HCT 116 lines (2.) and the SW480 WRN-knock-out models (3.) in the revised version of this manuscript as Figure 2—figure supplement 2 and Figure 2—figure supplement 3. This is of particular relevance since our results are in partial discrepancy to a recent preprint manuscript reporting the full reversion of WRN dependency in the MLH1/MSH3 reconstituted HCT 116 +ch3 +ch5 model (Chan et al., 2019 bioRxiv preprint available at https://doi.org/10.1101/502070). In our experiments, we only detect a minor improvement in viability upon WRN depletion in HCT 116 +ch3 +ch5 model. We have also revised the Discussion section accordingly.</p><p>It is plausible that WRN dependency is a consequence of alterations in genetic targets of MSI (i.e. genes harboring repetitive DNA sequences that are particularly vulnerable to the loss of MMR activity). To this end, we analyzed the effect of siRNA-mediated knock-down of genes commonly mutated in MSI-H cancer cell lines on viability of parental vs. WRN-knock-out SW480 cell lines. We did not observe an increased dependency on any of the genes tested the context of concomitant WRN loss. This argues against an acute synthetic lethal interaction of WRN and MSI target genes. However, we cannot rule out synthetic lethal interactions based on combined loss of MSI target genes and have addresses this accordingly in the Discussion section of the revised manuscript.</p><fig id="respfig2"><object-id pub-id-type="doi">10.7554/eLife.43333.022</object-id><label>Author response image 2.</label><caption><title>Left panel: List of MSI target genes and positive/negative control genes included in the siRNA knock-down analysis.</title><p>Cyclophilin was included as a negative control gene; PLK1, PSMA1 and SGO1 are used as positive control genes. siRNA targeting WRN was also include in the analysis. NTC, non-targeting control siRNA. Right panel: Effect of siRNA-mediated knock-down of MSI target gens on viability of parental and WRN-knock-out SW480 cell lines.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-43333-resp-fig2-v1"/></fig><disp-quote content-type="editor-comment"><p>3) WRN inhibitors need to be referenced and discussed more fully. In addition to the Rosenthal et al., 2010 reference, at least two WRN inhibitors have been around for 5+ years. They are highly and directly relevant to the topic of this manuscript, and are being pursued in other clinical contexts (see, e.g., Moles et al., 2016) that may provide additional insight. These inhibitors are readily available, and the authors' results make a straight-ahead prediction of what a dose-response outcome should be in their CRC cell line panels to provide a bit of pre-clinical data. The authors should acquire the WRN inhibitors and do dose-response curves on their MSI-H and MSS cell lines, and show that their WRN KO lines are insensitive (or largely insensitive) as a demonstration of target specificity.</p></disp-quote><p>We thank the reviewers for pointing out the use of published WRN inhibitors in the context of this study and we agree that it is highly relevant to assess the potential clinical value of our findings with the available chemical matter.</p><p>We have tested two structurally related WRN inhibitors, NSC 19630 (Aggarwal et al., 2011) and NSC 617145 (Aggarwal et al., 2013) and a chemical probe for the RecQ helicase BLM (Rosenthal et al., 2010) across a panel of MSS and MSI cell models. Both NSC 19630 and NSC 617145 affected cell viability in 7-day dose-response proliferation assays with IC<sub>50</sub> values below 10 µM in the majority of the tested cell lines (see Author response table 1). However, MSI-H CRC and endometrial carcinoma cell lines did not show increased sensitivity to treatment with the two WRN inhibitors compared to MSS cell models. The BLM inhibitor ML-216 was largely ineffective in the majority of cell lines at concentrations up to 10 µM. As a positive control, we included the pan-HDAC inhibitor panobinostat which showed potent inhibition of cell viability in the nM range across all cell models.</p><p>We have included two SW480 monoclonal cell lines with an engineered deletion of WRN in order to assess the on-target activity of the WRN inhibitors. Both SW480 WRN knock-out lines display sensitivities lower or similar to the parental cell line or a WRN-proficient SW480 monoclonal cell line. In the absence of the protein target this indicates that the observed toxicity of the WRN inhibitors might be at least in part attributable to non-WRN related off-target effects.</p><p>While these results do not preclude on-target activities of the tested WRN inhibitors in line with the literature data, we suspect that the inhibitors lack the potency and selectivity required for the cellular assessment of WRN function in the context of this study. Since the potential off-target activities pose a challenge in interpreting the cellular effects compared to the genetic inactivation of WRN, we have not included this data in the revised version of this manuscript. We have included the references to the WRN inhibitors NSC 19630 and NSC 23867477 in the revised Discussion section of the manuscript.</p><table-wrap id="resptable1" position="float"><object-id pub-id-type="doi">10.7554/eLife.43333.023</object-id><label>Author response table 1.</label><caption><title>Cell lines were plated at initial densities of 1000 or 2000 cells per well of a 96-well plate.</title><p>The following day, cells were treated with the indicated inhibitors at concentrations ranging from 10 to 0.04 µM (0.5 to 0.002 µM for panobinostat). Cell viability was determined 7 days after treatment. Data for NSC 19630, ML-216 and panobinostat are representative IC<sub>50</sub> values from three experiments, NSC 617145 IC<sub>50</sub> values are from a single analysis.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><bold>Tumor Type</bold></td><td><bold>MSS/MSI status</bold></td><td><bold>Cell line</bold></td><td><p><bold>NSC 617145</bold></p> <bold>IC<sub>50</sub> [µM]</bold></td><td><p><bold>NSC 19630</bold></p> <bold>IC<sub>50</sub> [µM]</bold></td><td><p><bold>ML-216</bold></p> <bold>IC<sub>50</sub> [µM]</bold></td><td><p><bold>Panobinostat</bold></p> <bold>IC<sub>50</sub> [µM]</bold></td></tr><tr><td rowspan="7">CRC</td><td>MSS</td><td>SK-CO-1</td><td>7.09</td><td>3.11</td><td>&gt;10</td><td>0.011</td></tr><tr><td>MSS</td><td>SW480</td><td>2.14</td><td>3.32</td><td>&gt;10</td><td>0.028</td></tr><tr><td>MSS</td><td>SW480_wt_clone</td><td>1.83</td><td>4.09</td><td>&gt;10</td><td>0.018</td></tr><tr><td>MSS</td><td>SW480_WRN_KO_clone#1</td><td>1.73</td><td>2.64</td><td>&gt;10</td><td>0.016</td></tr><tr><td>MSS</td><td>SW480_WRN_KO_clone#2</td><td>1.38</td><td>3.73</td><td>&gt;10</td><td>0.022</td></tr><tr><td>MSI</td><td>HCT 116</td><td>8.87</td><td>4.99</td><td>4.40</td><td>0.012</td></tr><tr><td>MSI</td><td>RKO</td><td>&gt;10</td><td>6.39</td><td>&gt;10</td><td>0.044</td></tr><tr><td rowspan="3">Endometrial carcinoma</td><td>MSS</td><td>MFE-280</td><td>4.54</td><td>3.38</td><td>5.71</td><td>0.009</td></tr><tr><td>MSI</td><td>HEC-265</td><td>7.74</td><td>6.80</td><td>&gt;10</td><td>0.021</td></tr><tr><td>MSI</td><td>ISHIKAWA</td><td>&gt;10</td><td>5.55</td><td>&gt;10</td><td>0.016</td></tr><tr><td>Non-transformed</td><td>MSS</td><td>hTERT-RPE-1</td><td>4.34</td><td>5.54</td><td>&gt;10</td><td>0.035</td></tr></tbody></table><table-wrap-foot><fn><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p></fn></table-wrap-foot></table-wrap><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…]</p><p>Point for final acceptance:</p><p>Update the Abstract to reflect the major conclusion that the MLH1 WRN synthetic lethality is context dependent and not absolute.</p></disp-quote><p>The Abstract has been updated to reflect the new experimentation. We have included a statement that WRN dependence is not acutely linked to loss of MMR gene function, but rather a consequence of sustained MMR-deficiency. The Abstract has further been slightly modified to adhere to the 150 word limitation despite addition of the new information.</p></body></sub-article></article>